The influence of fibronectin modulation on tumor growth by Ghura, Hiba
Aus dem Institut für Immunologie und Serologie 
der Medizinischen Fakultät Mannheim 
(Direktor: Prof. Dr. med. Stefan Meuer) 
The influence of fibronectin modulation on tumor growth 
 
 
Inauguraldissertation 
zur Erlangung des Doctor scientiarum humanarum (Dr. sc. hum.) 
der 
Medizinischen Fakultät Mannheim 
der Ruprecht-Karls-Universität 
zu 
Heidelberg 
vorgelegt von 
Hiba Ghura 
 
aus 
Latakia (Syrien) 
2019 
 
Dekan:  Prof. Dr. med. Sergij Goerdt 
Referentin: Prof. Dr. med. Inaam Nakchbandi 
TABLE OF CONTENT 
 Page 
LIST OF ABBREVIATIONS ..................................................................... 1 
1 INTRODUCTION ................................................................................. 4 
1.1 Cancer ........................................................................................................... 4 
1.1.1 Exogenous factors that promote cancer .............................................. 4 
1.1.2 The genes involved in cancer development ......................................... 5 
1.1.3 The hallmarks of cancer ...................................................................... 5 
1.1.4 Tumor microenvironment ..................................................................... 6 
1.1.4.1 Immune cells ............................................................................................................... 6 
1.1.4.2 Cancer-associated fibroblasts...................................................................................... 9 
1.1.4.3 Pericytes ...................................................................................................................... 9 
1.1.4.4 Extracellular matrix (ECM) ......................................................................................... 10 
1.1.5 The metastasis .................................................................................. 10 
1.1.5.1 The epithelial-to-mesenchymal transition (EMT)...................................................... 11 
1.1.5.2 Invasion ..................................................................................................................... 11 
1.1.5.3 Intravasation .............................................................................................................. 11 
1.1.5.4 Survival of metastatic cells in thecirculation ............................................................. 11 
1.1.5.5 Extravasation ............................................................................................................. 12 
1.1.5.6 Micrometastasis formation (premetastatic niche) ................................................... 12 
1.1.5.7 Metastatic colonization ............................................................................................. 12 
1.2 Fibronectin ................................................................................................... 13 
1.2.1 Fibronectin isoforms .......................................................................... 14 
1.2.1.1 EDA fibronectin.......................................................................................................... 14 
1.2.1.2 EDB fibronectin .......................................................................................................... 14 
1.2.1.3 The variable region .................................................................................................... 15 
1.2.2 Fibronectin interactions and physiological functions .......................... 15 
1.2.3 Role of fibronectin in cancer .............................................................. 16 
1.2.4 Fibronectin as a therapeutic target in cancer ..................................... 17 
1.3 The goal of the work .................................................................................... 18 
2 MATERIAL AND METHODS ............................................................. 19 
2.1 Materials ...................................................................................................... 19 
2.1.1 Instruments ........................................................................................ 19 
2.1.2 Companies ........................................................................................ 20 
2.1.3 Chemicals and reagents .................................................................... 22 
2.1.4 Media, buffers and solutions .............................................................. 24 
2.1.5 Used materials ................................................................................... 26 
2.2 Animal experimentation methods ................................................................ 28 
2.2.1 Animals .............................................................................................. 28 
2.2.2 Anesthesia of laboratory animals ....................................................... 28 
2.2.3 Intratibial injection of human breast cancer cells ............................... 29 
2.2.4 Bioluminescence imaging .................................................................. 29 
2.2.5 Radiography of bone lesions ............................................................. 30 
2.2.6 B16 - Melanoma - animal experiment model ..................................... 30 
2.2.7 Therapeutic treatment with peptides .................................................. 30 
2.2.8 Killing of the experimental mice ......................................................... 31 
2.3 Cell biology methods ................................................................................... 31 
2.3.1 Murine melanoma cell line B16-F10 .................................................. 31 
2.3.2 Human breast cancer cell line MDA-MB-231B/luc+............................ 31 
2.3.3 Isolation of immune cells from tumors ............................................... 32 
2.3.4 Depletion of immune cells from tumors .............................................. 32 
2.3.5 Determination of cell number ............................................................. 32 
2.3.6 Passaging and preparation of tumor cells for in vivo injections ......... 32 
2.4 Protein biochemical methods ...................................................................... 33 
2.4.1 Production of matrix lysates ............................................................... 33 
2.4.2 Production of protein lysates for analysis of western blot or ELISA ... 33 
2.4.3 Protein concentration by Bradford-assay ........................................... 33 
2.4.4 ELISA (Enzyme linked immunosorbent assay) .................................. 34 
2.4.5 Human and murine plasma fibronectin ELISA ................................... 34 
2.4.6 SDS gel electrophoresis .................................................................... 34 
2.4.7 Western blot ...................................................................................... 35 
2.4.8 Purification of peptides using a nickel-NTA column ........................... 36 
2.5 Molecular biology methods .......................................................................... 37 
2.5.1 Detection of mycoplasma by PCR ..................................................... 37 
2.5.2 RNA isolation and the reverse transcription of RNA .......................... 37 
2.5.3 Flow cytometry analysis ..................................................................... 37 
2.6 Histological methods ................................................................................... 38 
2.6.1 Preparation of tumor sections ............................................................ 38 
2.6.2 Immunohistochemical staining of frozen sections .............................. 38 
2.7 Statistical evaluations .................................................................................. 39 
3 RESULTS .......................................................................................... 40 
3.1 Confirming of the role of fibronectin of cancer cells in tumor growth ........... 40 
3.1.1 Knocking down of fibronectin in MDA cells ........................................ 40 
3.1.2 Induction of local bone metastasis ..................................................... 41 
3.1.3 Analysis of tumor growth ................................................................... 41 
3.1.4 Radiographic analysis of osteolytic lesions ........................................ 41 
3.1.5 Investigation of immune cells in MDA tumors .................................... 42 
3.2 Investigation of the effect of fibronectin accumulation inhibitor peptides in MDA 
human breast cancer model ................................................................................. 43 
3.2.1 Investigation of the effect of recombinant pUR4 and its Scrambled 
peptide on fibronectin of MDA cells in vitro ..................................................... 43 
3.2.2 Investigation of the effect of recombinant pUR4 on MDA tumor growth 
in vivo 44 
3.2.3 Investigation of pUR4 entry into MDA tumors .................................... 45 
3.2.4 pUR4 decreases fibronectin content of MDA tumors ......................... 46 
3.2.5 Radiographic analysis of MDA tumors before and after of recombinant 
peptides injection ............................................................................................ 46 
3.2.6 Investigation of immune cells in MDA tumors treated with recombinant 
peptides .......................................................................................................... 48 
3.2.7 Investigation of cancer and stromal cells in MDA tumors treated with 
recombinant peptides ..................................................................................... 49 
3.3 Evaluation of the effect of synthetic peptides in MDA tumors ...................... 50 
3.3.1 Investigation of the effect of synthetic pUR4 and its scramble on 
fibronectin of MDA cells in vitro ...................................................................... 50 
3.3.2 Investigation of the effect of synthetic pUR4 and its scramble peptide in 
MDA cells in vivo ............................................................................................ 50 
3.3.3 Evaluation of fibronectin content of MDA tumors treated with synthetic 
peptides .......................................................................................................... 51 
3.3.4 Radiographic analysis of MDA tumors treated with synthetic peptides
 52 
3.3.5 Evaluation of immune cells of MDA tumors treated with synthetic 
peptides .......................................................................................................... 53 
3.3.6 Evaluation of cancer and stromal cells of MDA tumors treated with 
synthetic peptides ........................................................................................... 54 
3.4 Effect of pUR4 in immunocompetent mice .................................................. 54 
3.4.1 Investigation of the effect of recombinant pUR4 and its scramble peptide 
on fibronectin of B16 melanoma cells in vitro ................................................. 54 
3.4.2 Investigation of the effect of synthetic pUR4 and its scramble peptide on 
fibronectin of B16 melanoma cells in vitro ...................................................... 55 
3.4.3 Investigation of the effect of synthetic peptides on B16 tumors growth in 
vivo 56 
3.4.4 Effect of the synthetic pUR4 on the immune cells of B16 tumors ...... 57 
3.4.5 Effect of the synthetic pUR4 on cancer and stromal cells of B16 tumors
 59 
3.5 Evaluation of modified pUR4 effect on MDA cells ....................................... 59 
3.5.1 Evaluation of modified synthetic peptides in vivo ............................... 60 
3.5.2 Evaluation of fibronectin content in MDA tumors treated with synthetic 
modified peptide ............................................................................................. 61 
3.5.3 Radiographic analysis of MDA tumors treated with the synthetic 
modified peptide ............................................................................................. 61 
3.5.4 Characterization of immune cells in MDA tumors treated with the 
synthetic modified peptide .............................................................................. 62 
3.5.5 Characterization of cancer and stromal cells in MDA tumors treated with 
the modified synthetic peptides ...................................................................... 64 
3.6 Investigation of the effect of modified peptide in B16 melanoma cells ......... 64 
3.6.1 Investigation of the effect of synthetic modified peptide on fibronectin of 
B16 melanoma cells in vivo ............................................................................ 64 
3.6.2 Effect of the synthetic modified peptide on the immune cells of B16 
tumors in immune competent mice ................................................................. 65 
3.6.3 Effect of the synthetic modified peptide on B16 melanoma cells and 
stromal cells of B16 tumors in immune competent mice ................................. 66 
3.7 Investigation of the fractions of the modified synthetic peptide in vitro ........ 67 
3.8 Cytokines expression of MDA tumors .......................................................... 69 
3.9 Immunohistochemical staining of MDA tumors ............................................ 70 
4 DISCUSSION .................................................................................... 73 
4.1 Effect of tumor-cell-fibronectin on tumor growth .......................................... 73 
4.1.1 Knock down of fibronectin in MDA-MB-231 cells ............................... 73 
4.1.1.1 Effect on the growth of MDA-MB-231B / luc + - breast cancer cells ........................ 73 
4.2 Modulation of fibronectin of cancer cells using a bacterial peptide .............. 74 
4.2.1 pUR4 inhibits fibronectin accumulation of human breast cancer cells in 
vitro and reduces cancer growth in vivo ......................................................... 74 
4.2.2 pUR4 diminishes tumor growth of murine B16 melanomas ............... 75 
4.2.3 The effect of the modification of pUR4 in vivo and in vitro ................. 76 
4.3 Changes in the expression of cytokines profile of tumors ............................ 77 
5 SUMMARY ........................................................................................ 79 
6 REFERENCES .................................................................................. 80 
7 CURRICULUM VITAE ....................................................................... 94 
8 ACKNOWLEDGEMENT .................................................................... 96 
 
LIST OF ABBREVIATIONS 
1 
 
LIST OF ABBREVIATIONS 
Alb  Albumin 
Ang-1  Angiopoietin-1 
bp  Base pairs 
BSA  Bovine serum albumin 
CAFs  Cancer associated fibroblasts 
CD Cluster of differentiation 
CD1  Caesarean derived 1 
cFN Cellular fibronectin 
COX  Cyclooxygenase enzyme 
cpp Cell penetrating peptides  
CT  Control 
CTLs  Cytotoxic T lymphocytes cells 
DAPI  4,6-diamidino-2-phenylindole 
DMEM  Dulbecco's modified eagle medium 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
dNTP  Deoxyribonucleotide triphosphate 
D-PBS  Dulbecco's PBS 
ECM  Extracellular matrix 
EDA  Extra domain A 
EDB  Extra domain B 
EGF  Epidermal growth factor 
ELISA   Enzyme linked immunosorbent assay 
EMMPRIN  Extracellular matrix metalloprotease inducer 
FCS  Fetal calf serum 
FGFs  Fibroblasts growth factors 
Fig.  Figure 
FN  Fibronectin 
Foxn1  Forkhead box N1 
FUD  Functional upstream domain 
G418  Geneticin 
H2Od Distilled water 
H2Odd  Double distilled water 
HBEGF  Heparin-binding EGF-like growth factor 
HBV  Hepatitis B virus 
HPV  Human papilloma viruses 
HRP  Horseradish peroxidase 
i.p. Intraperitoneal 
IGF-1  Insulin-like growth factor 1 
IgG  Immunoglobulin G 
IgM  Immunoglobulin M 
IL  Interleukin 
iNOS Induced nitrogen synthetase 
JNK  Jun N-Terminal Kinase 
Kd Knockdown 
kDa Kilo Dalton 
LIST OF ABBREVIATIONS 
2 
 
LDV  (Leu-Asp-Val)  
LOX  Lysyl oxidase 
MSCs Mesenchymal stem cells 
Maspin Mammary serine protease inhibitor 
MCP-1  Monocytes chemotactic protein-1 
M-CSF  Macrophages colony stimulating factor  
MDSC  Myeloid-derived suppressor cells 
MFI  Mean fluorescence intensity 
MIF  Migration inhibitory factor 
min  Minute 
mM  Millimoles 
MMP  Matrix metalloprotease 
MPI  Max Planck Institute 
mRNA  Messenger RNA 
MSC  Mesenchymal stem cell 
NF-κB  
 
Nuclear factor 'kappa-light-chain-enhancer' of 
activated B-cells 
NK  Natural Killer 
ns  Not significant 
oFN Oncofetal fibronectin 
OPN  Osteopontin 
P53  Tumor protein 
PBS  Phosphate buffered saline 
PBS-T  Phosphate buffered saline-Tween 
PCR  Polymerase chain reaction 
PDGF  Platelet derived growth factor 
PD-L1  Programmed-death-ligand 
Pen / Strep  Penicillin/Streptomycin 
pFN Plasma fibronectin 
qPCR  Quantitative real time PCR 
RANKL  Receptor activator of NF-κB ligand 
RB1 Retinoblastoma 
REDV  (Arg-Glu-Asp-Val) 
RGD  Arginine-glycine-aspartic acid 
RLU  Relative luminescence unit 
RNA  Ribonucleic acid 
RNAi  RNA interference 
RT  Room temperature 
s  Second 
SDF-1  Stromal cell-derived factor 1  
shRNA  Short hairpin RNA 
siRNA  Small interfering RNA 
TAMs  Tumor associated macrophages 
Taq Thermsus aquaticus polymerase 
TBE  Tris-boric acid EDTA 
TBS Tris buffered saline 
TBS-T  Tris buffered saline-Tween 
TGF  Transforming growth factor 
Th  T helper cells 
TNF  Tumor necrosis factor 
LIST OF ABBREVIATIONS 
3 
 
TNF-α Tumor necrosis factor-α 
UV  Ultraviolet 
VCAM-1  Vascular cell adhesion molecule 1 
VEGF  Vascular endothelial growth factor 
VEGFR1+    Vascular endothelial growth factor receptor 1 positive 
vs.  Versus 
αMEM  Advanced minimum essential medium 
α-SMA  α-smooth muscle actin 
INTRODUCTION 
4 
 
1 INTRODUCTION 
1.1 Cancer 
Cancer is a life-threatening disease with uncontrolled growth of cells that have a 
potential to spread in the body. 9.6 million deaths from cancer worldwide were recorded 
in 2018 and more than four in ten of all cancer deaths was caused by lung, liver and 
gastrointestinal cancer. Moreover, 17 million new cases of cancer were reported in 
2018. Therefore, developing curable therapeutics approaches is important [1]. 
1.1.1 Exogenous factors that promote cancer 
Many exogenous factors that could be involved in cancer promotion were recognized. 
These factors are chronic inflammation, tobacco smoke, alcohol, radiation, stress and 
diet [2]. Chronic inflammation due to viral infection is responsible for 15% of cancer 
cases worldwide. For example, human papillomaviruses (HPVs) and hepatitis B virus 
(HBV) are leading contributors to the development of cervical cancer and liver cancer, 
respectively [3, 4]. Furthermore, tobacco is a major risk factor for cancers of the 
respiratory system, bladder, kidney and stomach. Its carcinogenic effect arises from its 
ability to enhance chronic inflammation. It acts as a tumor stimulus by inhibiting 
apoptosis and promoting angiogenesis On the other hand, it leads to mutations in 
critical genes and disables their functionality such as TP53 and KARS genes by 
specific chemicals such as aromatic amines, aldehydes, tobacco-specific nitrosamines 
and polycyclic aromatic hydrocarbons. Epidemiological data also suggest that alcohol 
consumption is carcinogenic. Many findings correlated the immune inhibition effects of 
alcohol with tumor development and metastasis [5, 6]. However, its mechanism needs 
to be further clarified [7]. Mutations in DNA which lead to cancer could also be caused 
by radiation especially ionizing radiation and ultraviolet (UV) radiation. Ionizing 
radiation is another cause of lung cancer and most of its sources come from the 
radioactive elements in nature [8]. UV radiation which comes from the sunlight is 
recognized as a risk factor for melanoma and other skin cancers [9]. There is also an 
epidemiological link between obesity and cancer incidence and the mechanism of that 
arises from the hormonal imbalance which affects normal metabolic pathways and 
especially the estrogen hormone which is known to promote cell proliferation [10]. 
Stress could also affect the secretion of the steroid hormone cortisol and that may 
contribute to the development of some forms of cancers [11]. It was reported that stress 
response can affect cancer progression by different mechanisms. Chronic stress 
results in enhancing VEGF production and increasing burden of ovarian tumors [12]. 
Furthermore, catecholamines  production which is enhanced by stress response was 
implicated in an induction of IL-6 gene transcription which displays a crucial angiogenic 
effect in tumor progression [12]. Clinical studies also showed that ovarian cancer 
patients with low social interactions exhibit higher levels of IL-6 in plasma [13]. It was 
also shown that stress hormones support tumor migration and invasion by enhancing 
the ovarian tumor cells to produce matrix metalloproteinase and this process was 
confirmed in several other tumors including colon cancers and head and neck cancers 
[14-16] 
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1.1.2 The genes involved in cancer development 
The transformation of cancer cells from normal to malignant ones is mediated by genes 
which normally regulate cell growth and differentiation. That includes two main 
categories, the oncogenes and the tumor suppressor genes [17] 
Genes that are involved in coordinating of proliferation and apoptosis are characterized 
as proto-oncogenes that can transform into oncogenes as a result of mutations. These 
include point mutations, deletions, insertions, chromosomal rearrangement leading to 
replication of entire chromosomes and chromosome translocation or to gene 
amplification. These changes result in modifications either in the amount or in the 
location of genes. The classical model is due to the development of an oncogene, 
which is a mutation of one copy of a gene leading to tumor development [18]. Another 
model is due to inactivation of tumor suppressor genes that normally control cell cycle 
progression and restrain cell growth. These genes are normally recessive, requiring 
mutated maternal as well as paternal copies of these tumor suppressor genes for the 
tumor to develop. Nevertheless, the presence of only one mutated copy increases the 
risk of cancer development. P53 and RB1, two retinoblastoma genes are the most 
frequent genes inactivated in human cancers. Cancers, however, can have both, 
activation of oncogenes and inactivation of tumor suppressor genes together [19] 
1.1.3 The hallmarks of cancer 
Cancer cells can be distinguished from normal ones by several characteristics. Cell 
division of normal cells is tightly controlled whereas this control is lost in cancer cells. 
In addition, cancer cells are able to enhance their own growth. They can evade 
apoptosis [20], and become immortal in contrast to normal cells [21]. Angiogenesis, 
invasion and metastatic potential are the other properties of cancer cells that support 
cancer development [22]. 
 
 
 
 
Figure 1.1.3 The hallmarks of cancer 
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Special functional characteristics are required for the malignant transformation. Reproduced 
unmodified from [23]. 
1.1.4 Tumor microenvironment 
The tumor microenvironment is complex. Many cell types are recruited and 
extracellular matrix is produced. The cells consist of immune cells, fibroblasts, and 
vascular cells, some of which produce the matrix. These cells as well as matrix play a 
critical role in tumor growth and metastasis [22]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.4 Tumor microenvironment. 
The tumor microenvironment is a heterogenous and complex mixture of cellular components 
from mesenchymal origin like cancer associated fibroblasts (CAFs) and endothelial cells. CAFs 
are a prominent population and can support tumor progression by different mechanisms. The 
tumor also includes cells from hematopoietic origin (lymphoid and myeloid cells). Tumor 
associated macrophages (TAMs) are an abundant cell population in tumor tissue. They can 
be reprogrammed according to the tumor microenvironment, therefore their role in tumor 
progression is tumor type-dependent and needs to be further characterized. The noncellular 
component is the extracellular matrix (ECM). Reproduced unmodified from [24].  
 
1.1.4.1 Immune cells 
In tissue injury, inflammatory cells are recruited to the site of injury and then leave after 
having fulfilled their function. This is in contrast to conditions of chronic inflammation 
as is the case in cancer where immune cell function is mediated and controlled by 
various players in the tumor environment [25]. 
 
The leukocytes including the myeloid and lymphoid cells can be detected in all solid 
tumors [26, 27].The role of these cells in tumor progression depends on the tumor type 
and location [28].These infiltrating immune cells supply mutagenic signals that directly 
enhance the proliferation of cancer cells or indirectly through interactions with other 
cells [29]. The main mutagenic soluble mediators produced by infiltrating immune cells 
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include epidermal growth factor (EGF), tumor necrosis factor-α (TNF-α), transforming 
growth factor-β (TGF-β), fibroblasts growth factors (FGFs) and various interleukins and 
chemokines [29]. 
 
Immune cells are also involved in sustaining proliferation signals and activation of 
invasion and metastasis by modulating the structure and function of extracellular 
matrix. They achieve that by expressing various types of proteolytic enzymes like 
serine proteases, metalloproteases and cysteine proteases [30, 31]. These enzymes 
can induce angiogenic responses. They may also selectively cleave ECM molecules 
and adhesion molecules in order to avoid inhibitory growth signals [32, 33]. 
Furthermore, the immune cells as a part of stroma components play a crucial role in 
tumor migration and metastasis by their ability to produce matrix-metalloproteases 
(MMPs). For example, MMP-2 which is produced by macrophages and mast cells 
could activate TGF-β which in turn plays a key role in promoting the endothelial 
mesenchymal transition process (EMT) [34, 35]. On the other hand, it has been 
reported that this MMP-2 induces cleavage and alteration of specific ECM components 
such as laminin-5, especially the subunit Laminin-5-γ2, the cleavage of which leads to 
enhancing of breast epithelial cells migration [36]. Macrophages also produce MMP-7 
[35] which also in turn facilitates the invasion and metastasis by its ability to cleave 
macromolecules of ECM such as E-cadherin domain [37]. 
Hypoxia which is the prominent factor in angiogenesis increases recruitment of 
immune cells. These cells produce various mediators that regulate angiogenesis such 
as VEGF, TNF-α, TGF-β, platelet derived growth factor (PDGF), chemokines, matrix 
proteases enzymes and nitric oxide. These mediators then cooperate in order to 
induce angiogenesis [23, 38]. 
 
Macrophages in tumors are referred to as tumor associated macrophages (TAMs). In 
certain cancer types they represent the major component of the immune cells in the 
tumor microenvironment. In breast cancer for example they encompass 80% of the 
immune cell population [39]. The source of these cells is either the monocytes in the 
circulation which are recruited into tumors by chemotactic cytokines produced by 
tumors like monocytes chemotactic protein-1 (MCP-1), macrophages colony 
stimulating factor (M-CSF) and vascular endothelial growth factor (VEGF), or the 
macrophages can also proliferate locally in the tumor itself [40]. 
 
Macrophages have a pleiotropic role in tumor progression. They can exhibit pro- and 
anti-inflammatory functions depending on the signals that they get [41]. Thus, there 
are two types: M1 and M2 macrophages. M1 macrophages produce pro-inflammatory 
cytokines like TNF-α, IL1 and IL6, while M2 macrophages secrete mainly anti-
inflammatory cytokines like IL10 and TGF-β that support tissue remodeling and 
angiogenesis. This anti-inflammatory M2 phenotype seems to be the dominant one in 
tumors [40, 42].These M2 cells produce VEGF-A which is the main factor for promoting 
of angiogenesis by their capacity to produce MMP-9 that in turn increases the 
bioavailability of VEGF-A in the tumor environment [43]. 
 
The immune cells also provide the tumor environment with pro-invasive factors such 
as extracellular matrix metalloprotease inducer (CD147) and migration inhibitory factor 
(MIF). These factors are produced in response to TNF-α and activation of JNK 
signalling. The presence of these factors in tumor microenvironment results in 
secretion of MMP-2 and MMP-9 [44]. Immune cells of the macrophage type are 
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implicated in evading the immune-mediated destruction of cancer cells by their 
involvement in the blocking of cytotoxic T lymphocyte (CTL) activity in the tumor by 
different mechanisms [45]. It has been reported that this suppression is partially 
mediated by inducible nitric oxide synthase (iNOS) or arginase I which metabolizes L-
arginin and leads to the production of reactive oxygen species (ROS) which 
themselves have an immune suppressive behavior during tumor progression [45, 46]. 
Furthermore, TAMs provide the tumor microenvironment with a variety of chemotactic 
factors which also lead to the suppression of T cells and all T-regulatory (Treg) cell 
factors [45]. Another mechanism by which TAMs are implicated in suppression of CTLs 
is by upregulation of the checkpoint inhibitor called programmed cell death protein 1 
ligand (PDL-1) through IL10 production [45, 47]. 
 
Previous findings illustrated the role of the TNF-α related cytokine called receptor 
activator of NF-kB ligand (RANKL) that is produced by T cells and macrophages 
infiltrating prostate cancer. RANKL inhibits the expression of maspin gene which is a 
tumor suppressor gene that affects the expression of integrin adhesion molecules 
diminishing cell motility and invasion [48]. It has been reported that maspin could alter 
the integrin expression profile of invasive human breast cancer cells and inhibit their 
invasive capabilities. Maspin can induce an upregulation of α5 and α3 integrins and as 
a result increasing the ability of human breast cancer cells to be more adherent and 
less invasive [49]. This mechanism highlights the paracrine support of the tumor 
microenvironment in metastasis progression [50]. 
Myeloid-derived suppressor cells (MDSCs) are defined as immature myeloid cells not 
detected in healthy conditions. They are associated with chronic inflammation and play 
a role in tumor progression and drug resistance mainly due to their capacity to 
suppress T cells. Two main phenotypes of MDSCs were described in tumor-bearing 
mice. These are the monocytic MDSCs (M-MDSCs) and the granulocytic MDSCs (G-
MDSCs). M-MDSCs are characterized by CD11b+ LY6G- and LY6Chigh expression and 
experimental findings confirm their ability to differentiate into macrophages and 
dendritic cells [51, 52]. Their immune-suppressive activity is mediated by production of 
immune-suppressive cytokines and up-regulation of arginase-1 and inducible nitric 
oxide synthase (iNOS) [53]. G-MDSCs are defined by CD11b+ LY6Ghigh and LY6C- 
expression. The immune-suppressive mechanism of G-MDSCs is different from M-
MDSCs and needs contact with T cells for a prolonged period of time [54]. G-MDSCs 
were described to have immunosuppressive characteristics on CD8+ T cells by 
different mechanisms. Some studies had already shown that the immunosuppressive 
function is mediated by ROS-dependent mechanism although they expressed high 
levels of arginase-1 [55]. On the other hand, it has been reported that their inhibitory 
functions do not need the presentation of MHC-class I molecules [56]. Finally, 
Interferon-γ (IFN-γ) was also described to be implicated in the suppression of these 
cells [56]. Whereas M-MDSCs were reported to induce CD8+ Tcell suppression by a 
nitric-oxide- (NO)-mediated mechanism and partially by IFN-γ/STAT1 dependent 
mechanism [57]. Other T cells play a crucial regulating role in tumor microenvironment 
too. The presence of CD4+ T helper and CD8+ cytotoxic lymphocytes (CTLs) predicts 
a better prognosis [58]. Th1 cells, which are characterized by having anti-tumor effect 
by producing IFN-γ, TNF-α and IL2. IFN-γ enhances the expression of PD-L1 [59] 
which in turn inhibits the immune system. IL17 produced by Th17 cells also supports 
the activity of IFN-γ produced by Th1 in inducing secretion of CXCL9 and CXCL10, 
two T cell chemoattractants [60]. Furthermore, long-term contact of T cells in tumor 
microenvironment with tumor cells leads to the development of exhausted T cells with 
limited anti-tumor effect [61]. T-regulatory cells (Tregs) are a subset of CD4+ T cells 
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that inhibit cytotoxic anti-tumor effects of cytotoxic T cells (CTLs) and natural killer (NK) 
cells, thus exerting immune-suppressive activity [62, 63], either directly or by secreting 
cytokines such as IL10 and TGF-β [64, 65]. Another subset of T cells are the Th2 cells 
that produce cytokines like IL4, IL5 and IL13 and inhibit T cells that mediate cytotoxicity 
of tumor cells [66-68]. 
 
B cells can also affect tumor by regulating blood coagulation and enhancing 
complement activation [69, 70]. They may exert an anti-tumor effect by presenting 
tumor antigens to CTLs. but can also exert a pro-tumor effect by producing cytokines 
such as IL10, activation of Treg cells and suppressing Th1 cells [71, 72] 
 
1.1.4.2 Cancer-associated fibroblasts 
Cancer-associated fibroblasts (CAFs) are part of tumor stroma. They include at least 
two main sub-populations: fibroblasts that provide structural support of tissues and 
myofibroblasts. Myofibroblasts are found in chronic inflammation and also express α-
smooth muscle actin (α-SMA) [73]. They are heterogeneous since they may originate 
from various precursors such as fibroblasts, endothelial cells, epithelial cells and 
mesenchymal stem cells [74, 75]. CAFs are an important contributor to tumor 
proliferation, invasion and metastasis [76].  
 
Because of the heterogeneous origin of CAFs they may support cancer cells to evade 
growth suppressors [38]. They produce proteases which in turn damage tissue 
structure that normally suppresses growth. They produce survival factors such as 
insulin-like growth factor 1 (IGF-1) and insulin-like growth factor 2 (IGF-2) [77, 78]. 
Moreover, they are implicated in ECM formation and secretion of remodeling enzymes 
like MMPs, which in turn facilitate metastasis [31]. For example, CAFs, in response to 
TNF-α and TGF-β in tumor, secrete MMP-9 that degrades the main constituents of 
basement membrane which are type IV collagen and laminin [79, 80]. 
 
CAFs play an important role in angiogenesis by producing VEGF, FGFs, and PDGF 
an storing them in the matrix [81]. By releasing ECM-degrading enzymes they enrich 
the tumor environment with these factors [77, 82]. CAFs also secrete CXCL12 that 
recruits endothelial precursors [74]. In addition, they contribute to recruitment of 
proangiogenic immune cells [83, 84]. TGF-β produced by CAFs inhibits cytotoxic T 
cells (CTLs) and NKT cells further enhancing tumor growth [85, 86] .  
Lastly, CAFs reprogram cell metabolism by producing metabolites such as lactate and 
pyruvate via anaerobic glycolytic pathway. Thus, they work as an energy supplier for 
cancer cells [87-90].  
1.1.4.3 Pericytes 
Pericytes are the perivascular fibroblastic-like cells. They are involved in various steps 
of cancer development [91]. By secreting a variety of growth factors, pericytes can 
stimulate the proliferation of endothelial cells and thus enhance angiogenesis. On the 
other hand, they induce endothelial cells migration and extracellular matrix modulation 
by proteases secretion [92-94]. Several studies have shown the ability of pericytes to 
differentiate into different cell types such as adipocytes, chondrocytes, smooth muscle 
cells and fibroblasts [95]. Pericytes have also properties that they share with 
mesenchymal stem cells (MSCs) including partial similarity in surface markers and the 
ability to migrate in response to chemotaxis [96]. 
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1.1.4.4 Extracellular matrix (ECM) 
The non-cellular component of tumor microenvironment is the extracellular matrix 
composed of macromolecules including proteins such as fibronectin and collagen, 
glycoproteins and polysaccharides that form a three-dimensional network of a high  
degree of complexity [97]. The main functions of the ECM are in allowing cell adhesion, 
promoting differentiation and mediating cell-cell communications [98]. In cancer 
microenvironment, ECM architecture is deregulated and these changes lead to 
alteration in its biological and physical characteristics and functions [99] 
 
1.1.5 The metastasis 
Cancer mortality is related to metastasis in 90% of the cases [100]. It is a complex 
process involving several steps and includes invasion, intravasation, migration, 
extravasation, and proliferation of cancer cells in the secondary site of the cancer 
growth called metastatic site [101]. It needs a coordinated cross-talk among these 
various steps to avoid cancer cell loss at any of the steps [102] 
 
 
Figure 1.1.5. Schematic presentation of metastatic cascade.  
The complex metastasis process starts with dissemination of cancer cells from the primary 
sites (local invasion and intravasation), transmission and survival in the circulation followed by 
arrest at the secondary site (extravasation). After adapting to the new environment 
(micrometastasis formation), tumor cells start proliferation. Reproduced unmodified from [103].  
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1.1.5.1 The epithelial-to-mesenchymal transition (EMT) 
EMT is a program that takes place during embryonic development and in pathological 
conditions such as wound healing, tissue regeneration, fibrosis and cancer [104]. In 
tumors, EMT can be induced by hypoxia, TGF-β, FGF and EGF. This leads to loss of 
markers of epithelial cells (E-cadherin and cytokeratin-18) and expression of 
mesenchymal markers (α-SMA and vimentin). The process may be incompleted 
leading only to cells with different expression level of E-cadherin [105]. 
 
EMT is characterized by expression of transcription factors like Twist and Snail. Twist 
and Snail as transcription factors act as molecular switching keys of the EMT program. 
Their upregulation is required in metastatic carcinomas [106, 107]. It leads to 
downregulation of E-cadherin and upregulation of N-cadherin. This results in changes 
in cell-cell adhesion, cell-matrix adhesion and the cytoskeleton [108, 109]. It was also 
shown that Snail-induced EMT can facilitate tumor metastasis by inducing immune 
suppression [110].  
1.1.5.2 Invasion 
Invasion and migration are fundamental to metastasis formation. Cancer cells may 
locally invade either as a coherent multicellular unit via a process named collective 
invasion or as individual tumor cells [111]. The movement of individual cancer cells 
through the ECM can proceed through mesenchymal or amoeboid cell migration [112]. 
The mesenchymal mechanism is used by normal cells like smooth muscle cells, 
endothelial cells and fibroblasts and it is proteases-dependent [113]. These proteases 
such as MMPs degrade ECM allowing the cells to induce a breach in the basement 
membrane that organizes epithelial cells. The matrix provides signals through integrin-
mediated cell-matrix adhesions, and upregulation of MMP production is needed for 
invasion [114]. Cancer cells produce directly MMPs or stimulate the stromal cells to 
produce them [115]. The amoeboid cell migration is a protease-independent 
mechanism requiring mechanical forces and is faster than mesenchymal migration 
[112, 116]. It leads to loss of ECM attachment and cell polarity [101, 117]. Tumor cells 
reorganize their cytoskeleton by changing cell-cell and cell-matrix adhesion which 
increases their ability to migrate. For example, modulation of collagen crosslinking 
through changing of integrin signalling leads to alteration of ECM rigidity and breast 
cancer progression [118]. 
1.1.5.3 Intravasation 
Intravasation refers to the entry of cancer cells into the lumen of lymphatic and blood 
vessels [119]. TGFβ supports both the invasion generally and penetration of blood 
vessels walls by mammary cancer cells [120]. Tumor associated microvasculature has 
weak interactions between the adjacent endothelial cells and often lacks pericyte 
coverage leading to an unstable structure and facilitating intravasation [121]. 
Cyclooxygenase-2 (COX-2), MMP-1 and MMP-2 were reported to stimulate neo 
angiogenesis and hence support the intravasation of breast cancer cells [122] 
1.1.5.4 Survival of metastatic cells in the circulation 
In the circulation cancer cells represent “metastatic intermediates” [123]. Once in the 
circulation cancer cells and platelets form micro-aggregates [102]. These allow the 
cancer cells to overcome the stress of loss of matrix attachment mediated by integrin 
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which is normally necessary for survival. It also protects them from immune cell action 
and the mechanical shear stress of blood flow. This process is mediated by fibronectin 
in the circulation as well as expression of L and P-selectins by cancer cells [124-127] 
1.1.5.5 Extravasation 
Extravasation requires adhesion and trans-endothelial migration. The paracellular 
migration is the dominant mechanism of extravasation. This requires disruption of 
endothelial cell junctions. Tumor cells can enhance this process by secretion of specific 
factors or expression of particular receptors. For example, it has been reported that 
the extravasation of breast cancer cells was initiated by the expression of the EGF-
receptor ligands such as heparin-binding EGF-like growth factor (HBEGF), the enzyme 
COX2, which mediates prostaglandin synthesis and the metalloproteinase MMP1 and 
MMP2 that induce the matrix remodeling. Extravasation of melanoma is augmented by 
osteonectin secretion and remodeling of endothelial junctions via binding to vascular 
cell adhesion molecule 1 (VCAM-1). The induction of programmed necrosis in 
endothelial cells is another mechanism used by tumor. The recruitment of the myeloid 
cells and platelets to the surrounding of tumor cells after their arrest to the vascular 
bed not only supports their survival in the circulation but also can promote the 
extravasation [128]. 
1.1.5.6 Micrometastasis formation (premetastatic niche) 
Forming a micrometastasis requires the survival of the tumor in a distant tissue. The 
new microenvironment is different from the primary tumor site. The premetastatic niche 
model was suggested to clarify how cancer adapt to the new site. Data suggest that 
the primary tumor by releasing systemic signals can change the composition of this 
niche. Lysyl oxidase (LOX) from the primary tumor leads to fibronectin production in 
the future niche. The receptor α4β1 on the hematopoietic progenitor cells can mediate 
their localization to the hematopoietic niche. This integrin can also bind to the vascular 
cell adhesion molecule-1 (VCAM-1 or CD106) which is expressed on stromal and 
endothelial cells. Various cells are implicated in releasing a various of chemoattractant 
factors from the ECM like stromal cell-derived factor 1 (SDF-1) + by their ability to 
secrete MMP9 [129]. These activities lead to the homing of the cancer cells to the 
future metastatic site.  
1.1.5.7 Metastatic colonization 
The cancer cells that reaches the secondary site depends on the stromal components 
of the new environment [102]. The concept of the “seed-and-soil” observed by Stephen 
Paget suggests that certain cancer cells prefer metastastic sites that are more suitable 
for their survival and proliferation [130]. Melanoma cells failed to metastasize to 
subcutaneous grafts of renal tissues, whereas they metastasize successfully to the 
subcutaneous grafts of lung tissues [131]. Specific genes facilitate metastasis of breast 
cancer to either liver [132], lung [133], bone [134] or brain [124]. Various osteolytic 
cytokines, such as TGF- modify the crosstalk between osteoclasts and osteoblasts 
and enhances bone metastasis [134]. Since bone marrow-derived cells recruitment to 
the metastatic site is required for metastasis, systemic molecules released from cancer 
such as osteopontin (OPN) and SDF-1 are also important [135, 136]. Angiogenesis is 
also needed [137, 138], and is stimulated by lack of oxygen (hypoxia) and VEGF 
production [139]. 
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1.2 Fibronectin 
Fibronectin (FN) is a dimer of 500 kDa glycoprotein that is found in the ECM and in 
various body fluids. FN is either found in vivo in its soluble form (produced by 
hepatocytes) or in an insoluble form (cellular), that is incorporated in the matrix around 
or on the cells such as fibroblasts, epithelial cells, endothelial cells, and osteoblasts 
[140, 141]. 
 
Its two monomer chains are linked to each other at their C-terminal by disulfide bridges.  
It consists of three types of modules: type I, II, and III, which are included in each 
monomer and are responsible for the functional properties of fibronectin. Type I and 
type II modules contain disulfide bonds whereas type III modules do not [142, 143]. 
The 12 type I modules at the N (amino) and C (carboxyl) terminal can be involved in 
the binding of fibrin and collagen. Type II modules are also involved in the binding of 
collagen. Type III modules include RGD sequence that is composed of 3 amino acids 
(arginine, glycine and aspartic acid) and is involved in binding to cell surface receptors 
in addition to other binding sites for integrins and heparin [144].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Schematic representation of plasma fibronectin structure [145] 
The two monomers of fibronectin are linked to each other at the C-terminal by disulfide bridges. 
Each monomer is composed of repeating units of three different modules (type I (hexagons), 
type II (quadrants) and type III (cylinders). The functional domains of fibronectin are 
characterized by the corresponding binding patterns. Reproduced unmodified from [145]. 
 
Assembly of fibronectin means that the protein gets extended and that happens when 
it binds to the receptors on the cell surface. Two main methods were characterized for 
initiation of assembly. The first one requires the interaction of cell surface integrins with 
the integrin-binding motif in 10FNIII (RGD) [146]. Another mechanism proposed the 
interaction between the N-terminal 70-kDa domain of fibronectin including N-9FNI with 
the cell surface [147, 148]. It has been reported that the kinetics of binding of N-9FNI 
to the cell surface is similar to that of fibronectin [149]. Therefore, N-9FNI has been 
described as a negative inhibitor of fibronectin assembly [150]. The bacterial peptide 
pUR4 that binds to a 70-kDa domain of fibronectin which comprises the N-9FNI can 
inhibit FN assembly [151]. However, the N-5FNI is also important for assembly and the 
deletion of one FNI module in the N-5FNI abolishes the binding of N-9FNI to the cell 
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surface [152], therefore it seems that FN binds to collagen through several FNI 
modules. However, the binding sites in N-9FNI including NGF and IGD motifs [153, 
154] are not necessary for its binding to the region of assembly on the cell surface 
[155]. 
1.2.1 Fibronectin isoforms 
Fibronectin is encoded by a single gene and produced by several mammalian cell 
types, however it exists in several isoforms due to the alternative splicing patterns in 
the IIICS region, the presence or absence of the extra-domains A (EDA) or B (EDB) of 
the single fibronectin primary transcript as well as post translational modifications 
[156]. The IIICS region, which is modified by alternative splicing, is in a non-
homologous segment and is referred to as a variable region or IIICS (type-III 
connecting segment). This domain is structurally complex and is composed of 5 
sequences of amino acids. Within the main area of type III repeats, exclusion or 
inclusion of the fibronectin type III EDA and EDB domains [157-159] lead to the 
formation of several isoforms [160, 161]. This alternative splicing of the fibronectin pre-
mRNA is developmentally regulated and is also dependent on the cell type [162, 163]. 
Therefore, these isoforms differ in solubility, cell adhesion, and binding properties [164, 
165]. Taking into account the variants that result from posttranscriptional modifications 
of the EDA and EDB modules, 20 different fibronectin monomers can be generated in 
humans [144]. 
1.2.1.1 EDA fibronectin 
EDA isoform is the result of alternative splicing of precursor mRNA at the region 
between 11FNIII and 12FNIII which represents the complete 90 amino acid domain EDA 
or EIIIA domain [144, 166]. The EDA domain is >90% similar in mouse and human 
[167]. It is involved in critical functions including cell adhesion [168], mitogenesis and 
cell cycle progression [169], wound healing [170] and differentiation of myofibroblasts 
[171]. EDA is highly expressed during embryonic development but its presence in 
normal tissues in adulthood is restricted. However, it is produced during wound 
healing, atherosclerosis [172], pulmonary and liver fibrosis [173, 174] and in stroma of 
various cancer types [175]. EDA fibronectin is detected in normal vasculature [176, 
177]. In line with the requirement for fibronectin for angiogenesis and angiogenesis for 
tumor growth [178], EDA fibronectin was expressed in 50% of invasive ductal breast 
cancer in humans [179]. Moreover, fibronectin EDA was shown to mediate epithelial-
mesenchymal transition in lung and colorectal carcinomas [180, 181]. EDA fibronectin 
was also highly expressed in primary and metastatic melanoma lesion sections [182]. 
All of these functions induced by EDA FN might be caused by increasing its binding 
affinity to the integrin α5β1 [183], or due to its ability to bind to 41, 47, or 91 
integrin [184]. 
1.2.1.2 EDB fibronectin 
The EDB isoform is the result of an alternative splicing of precursor mRNA at the region 
between 7FNIII and 8FNIII which represents the complete 91 amino acid domain EDB 
or EIIIB domain [144, 166]. EDB domain is almost analogous in humans and mouse 
[165, 185, 186]. However, EDA and EDB isoforms show low similarity within species 
(28% in humans) suggesting that they have distinct functions [166]. The presence of 
the EDB domain induces activation of vascular endothelial growth factor expression 
and endothelial proliferation [187]. It is sometimes named oncofetal variant due to its 
high expression during development leading to some confusion with the isoform 
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containing O-glycosylations [188, 189]. However, many studies demonstrated that the 
EDB exon is more excluded in adults than the EDA exon [190, 191]. Its absence from 
the mature blood vessels but presence in newly formed blood vessels led to its use as 
a marker for angiogenesis [192].  
 
Deletion of the exons coding EDA and EDB in mice resulted in cardiovascular defects 
because of the importance of EDA and EDB variants in stabilization of blood vessels 
and in angiogenesis [193]. EDB was found in the vessels of breast carcinoma [179] 
and stroma of human colorectal cancers [194]. Furthermore, high expression in the 
blood vessels in Hodgkin and non-Hodgkin lymphoma was associated with more 
malignant forms [195]. In melanoma metastatic lesions, EDB was also highly 
expressed especially in comparison to the primary malignant melanoma [182].  
1.2.1.3 The variable region 
It is formed by a total of 120 amino acids and located between 14FNIII and 15FNIII [174]. 
Depending on alternative slicing, it can consist of a variety of chains including up to 
five sequences. Its presence is needed for its secretion, except in chondrocytes. The 
plasma fibronectin includes at least one variable region and it was reported that 
synthesized fibronectin lacking the variable region degraded, whereas it is often found 
in both chains of cellular fibronectin. Therefore, it might be required for the formation 
and stability of dimer fibronectin [196, 197]. 
1.2.2 Fibronectin interactions and physiological functions 
FN mediates various vital processes including cell differentiation, proliferation, 
adhesion and migration. FN and other components of extracellular matrix are crucial 
factors for embryogenesis [198]. It has been shown that FN is required for blood vessel 
formation, and in its absence leads to failure of vascular angiogenesis in mice and to  
early embryonic lethality [199]. It exerts its functions through binding to members of 
integrin receptors family [200]. 
 
Numerous integrin recognition sequences have already been characterized and 11 
integrin pairs are able to bind to fibronectin [144, 201]. Integrins are cell surface 
proteins consisting of heterodimers of an  and a  subunit. They mediate cell-cell and 
cell-matrix interactions [201]. The main sequence that mediates the cell adhesion 
functions of fibronectin is RGD sequence that is located in10FNIII domain and 
composed of three amino acids (Arg-Gly-Asp). It is also found in other cell adhesion 
proteins such as vitronectin and laminin [202, 203]. This motif binds to integrin α5β1 
and αvβ3 as well as others such asαvβ1, α8β1 and α9β1 [184]. The presence of the 
synergy sequence (PHSRN sequence) that is located in the 9FNIII repeats and 
composed of five amino acids (Pro-His-Ser-Arg-Asp) is required for the binding of RGD 
to 51 [204]. The LDV sequence (Leu-Asp-Val) and REDV (Arg-Glu-Asp-Val) which 
are found in the variable region of fibronectin are other cell recognition sequences that 
interact with α4β1 and α4β7 [144, 205]. The EDA domain also includes binding sites 
for α4β1, α4β7 and α9β1 integrins [206]. Fibronectin can also interact with heparan 
sulfate proteoglycans located on syndecans by its two main heparin binding domains. 
The stronger one is located at the C terminus and another one in the N terminus of 
fibronectin. Syndecans modify the cell response to fibronectin [207]. It has been shown 
that the connection between α5β1 integrin and syndecan-4 is required for the focal 
adhesion which occurs during the cell adhesion on fibronectin. Furthermore, integrin-
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syndecan interactions might be involved in cell adhesion to both laminin and vitronectin 
[208]. 
Two major fibrin-binding sites (Fibrin I and Fibrin II) were also detected in fibronectin 
and the most important one is found at the N terminus and is formed of 4FNI and 5FNI. 
Fibronectin interactions with fibrins affect cell adhesion and migration [209]. Collagen 
binding sites are found in the FNI and FNII repeats of fibronectin. Collagen is an 
important component of ECM. Collagen fibers mediate various physiological functions 
during embryonic development and modify cellular differentiation. It has been reported 
that the deposition of fibronectin into the matrix is required for the formation of a 
collagen matrix [209, 210]. The collagen binding site in fibronectin includes four FNI 
and two FNII modules which are (6FNI, 1-2FNII and 7-9FNI) and it is called gelatin-
binding domain (GBD). Using antibodies targeting this region leads to an inhibition of 
collagen deposition in fibroblasts in vitro [211]. Binding studies showed that 8-9FNI 
fragments bind preferably to collagen but the role of other regions in the gelatin-binding 
domain GBD is not clear. Furthermore, it was reported that collagen chains are also 
implicated in this interaction through specific binding repeats which have high affinity 
to 7-9FNI [212]. The mechanism of this interaction requires a sequence containing 
GESGE which is found in pUR4. This motif can bind with high affinity to 7-9FNI fragment 
of fibronectin suggesting that this repeat mimics collagen binding sites that were found 
in other bacterial matrix peptides [213]. Fibronectin is involved in many physiological 
activities such as wound healing. In healthy organisms, the inactive form of integrin on 
the hematopoietic cells in the circulation prevents fibril formation. However, when 
vascular injury develops, the platelets in the bloodstream aggregate and αIIbβ3 integrin 
is activated, and fibronectin fibrils are formed. Fibronectin in the clot acts as 
chemoattractant for many cells that are also required for wound healing such as 
leukocytes, fibroblasts, and endothelial cells [214, 215]. Furthermore, fibronectin plays 
a critical role in stabilization of clot by its covalent binding with fibrin that is mediated 
by the blood coagulation factor XIIIa and also by its cross-linking with collagen fibers 
which support platelets aggregation. It was also reported that fibronectin acts as an 
opsonin for phagocytosis to allow the removal of the debris and dead cells during tissue 
injury [214]. 
 
1.2.3 Role of fibronectin in cancer 
The participation of fibronectin in different stages of tumorigenesis by different 
mechanisms has already been confirmed in numerous studies. The high expression of 
total fibronectin and the extra domain (EDA) were associated with the upregulation of 
α5β1 integrin in malignant breast cancer lines [216]. Furthermore, the interaction 
between fibronectin and α5β1 integrin mediates downstream signaling of PI3-K/Akt 
which in turn down-regulates the tumor suppressor gene p53 and as a consequence 
enables the cancer cells to evade apoptosis which is one of defining feature of cancer 
[217]. Upregulated EDA in colorectal tumors and its interaction with its receptor α9β1, 
which in turn was highly expressed in CD133+CD44+ cells that are believed to initiate 
colon cancer, was required for tumor proliferation [218]. An immunosuppressive role 
of fibronectin has also been observed, since silencing of fibronectin by siRNA resulted 
in slowing of glioma growth in mice and that was in part explained by reduction of T-
regulatory cells (Tregs) which inhibit T helper cell action against cancer [219]. 
Importantly, EDA fibronectin activates the myeloid derived suppressor cells population 
that weaken the immune response against cancer confirming its pro-tumor effect [220]. 
The fibronectin isoforms EDA and EDB are also regulators of tumor growth by 
upregulating the pro-angiogenic VEGF [177, 187, 221]. Fibronectin also facilitates the 
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invasion of cancer cells by changing ECM stability [109] and by inducing the expression 
and secretion of certain matrix metalloproteases that dissolve the matrix surrounding 
the tumor cells and enable their entry into the vascular system [115, 222]. As cancer 
cell survival during circulation is also crucial for development of metastases, it has also 
been demonstrated that the fibronectin helps the tumor cells to bind to platelets 
protecting them from the immune system [223, 224]. 
 
1.2.4 Fibronectin as a therapeutic target in cancer 
Based on the crucial role of fibronectin in all stages of tumor progression, many 
potential fibronectin-dependent therapeutic approaches can be envisioned to treat 
cancer. 
 
Fibronectin can be targeted directly by inhibition of its production and that could be 
curable. Alternatively, one could try to prevent its accumulation such as by using pUR4.  
pUR4 is a bacterial peptide derived from F1 adhesion molecule of streptococcus 
pyrogens that inhibits FN polymerization by binding with high affinity to the N-terminal 
70-kDa part of FN. Its mechanism as a FN polymerization inhibitor in vitro was 
confirmed [151]. Furthermore, its administration in mice in which a partial ligation of 
the external and internal carotid arteries was performed diminished fibronectin and 
collagen accumulation and thus reduced the narrowing of the vessels [225]. The 
involvement of this peptide in the inhibition of other matrix proteins accumulation such 
as collagen I and tenascin-C was also elucidated in co-culture of breast cancer cells 
and fibroblasts in vitro [226]. The importance of FN in angiogenesis was shown in an 
in vivo model of breast and prostate cancer, where fibronectin was deleted in the 
circulation [127, 226].  
 
Targeting of fibronectin expression in the tumor could be another strategy for cancer 
therapy and that was investigated by RNA interference which led to silencing of 
fibronectin gene expression [219, 227]. Cell penetrating peptides (cpp) are peptides 
derived from viral proteins with some modifications consist of (10-30) amino acids and 
were used to deliver fibronectin siRNA in vitro [228]. Because of its ability to penetrate 
tumor cell membrane, they were used as a delivery vector for fibronectin siRNA to the 
tumor [229] and also for trans-vascular delivery of siRNA. Using these approaches, 
they were shown to be an optimistic, non-invasive and safe therapeutic molecules that 
can pass across the blood brain barrier [230]. 
 
Vaccinia viruses were also reported as a strategy for fibronectin targeting in malignant 
ovarian cancer and fibronectin of fibroblast in the tumor stroma [231] depending on an 
engineered established form that has an oncolytic effect. They were used for targeting 
fibroblasts in ovarian tumor stroma and they were able to infect them [232]. 
 
Based on the presented evidence, targeting of FN synthesis or accumulation might 
offer a good alternative to chemotherapy and inhibit angiogenesis and cancer growth. 
Once a good possibility has been established, one challenge is the delivery system 
which should specifically deliver the agent to the tumor site [233]. 
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1.3 The goal of the work 
Fibronectin is an extracellular matrix protein that is expressed in almost all types of 
cancers and plays a crucial role in tumor growth promotion, survival and resistance to 
therapy. We have shown that deleting fibronectin genetically in mice leads to smaller 
bone metastasis. Furthermore, higher fibronectin expression in breast and prostate 
cancer lesions shortens survival in affected patients. Under special circumstances 
fibronectin suppresses the ability of myeloid cells to fight cancer in vivo in mice. In a 
model of liver fibrosis, we had successfully used a peptide that prevents fibronectin 
fibril formation and hence matrix accumulation. We hypothesized that 
pharmacologically decreasing fibronectin accumulation in cancer will not only slow 
down cancer progression by suppressing angiogenesis but may additionally diminish 
cancer size by stimulating the immune response. Therefore, the main goal of my work 
is an investigation of fibronectin matrix manipulation as a therapeutic approach in 
cancer.
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2 MATERIAL AND METHODS 
2.1 Materials 
2.1.1 Instruments 
Instrument Producer 
Autoclave Systec GmbH, Wettenberg, GE 
Camera EOS 350 Digital Canon Inc., Tokyo, Japan 
CASY cell counter Roche, Mannheim, GE 
Centrifuge Type 1-14, Sigma Labor centrifuge, Biofuge 15, Heraeus 
Multifuge 1 S-R, Thermo Fisher Scientific Light Cycler 
2.0 sample carousel (20µl), Roche SORVALL® RC-5B 
PLUS Superspeed Centrifuge, Thermo Fisher Scientific 
Cryomikrotom Cryostat CM 3050, Leica 
Developing instrument Type CP1000, Agfa 
ELISA Reader Lab instruments Deutschland GmbH, Crailsheim, GE 
Flow cytometry LSRII, BD Bioscience 
Freezer -20°C Privileg, Stuttgart, GE 
Freezer -80°C  New Brunswick Scientific, Edison NJ, USA 
Freezing box #3043317, Nunc, Thermo Fisher Scientific 
Gel system Peqlab Biotechnologie GmbH, Erlangen, DE 
Gel documentation Bio-Rad Laboratories GmbH, Düsseldorf, GE 
Heating block Eppendorf, Hamburg 
Thermomixer compact Eppendorf, Hamburg, GE 
Incubator New Brunswick Scientific, Edison NJ, USA 
Laminar flow cabinet Thermo Fisher Scientific Inc, Waltham MA, USA 
Light cycler Light cycler 2.0 instrument, Roche 
Liquid nitrogen tank Messer Group GmbH, Sulzbach, GE 
Magnet Yellow line MSH basic, Carl Roth 
Micro-plate washer ASYS Hitech GmbH, Eugendorf, Austria 
Microscope Leica Microsystems, Wetzlar, GE 
Microscope Microscope DM IL, inverse routine microscope, Leica 
Vanox-S, Olympus, with sony camera (CCD) Biozero 
(BZ-8100), Keyence ECLIPSE Ti-E, Nikon 
Microwaves LG Electronics, Seoul, Korea 
pH meter Knick GmbH + Co. KG, Balingen, DE 
Pipet comfort classic IBS Integra Biosciences, Fernwald GE 
Plate washer Anthos fluidoType 24200, ASYS 
Pump Pharmacia LKB Pump P1, GE Healthcare Econo, Bio-
Rad 
Scanner CanoScanLiDE 60, Canon 
Shaking incubator New Brunwick Scientific, Edison NJ, USA 
Thermo cycler Biometra, Göttingen, GE 
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UV spectrophotometer Eppendorf, Hamburg, GE 
Vortex Bender and Hobein AG, Zürich, Switzerland 
Scale Kern and Sohn, Balingen, GE 
 
2.1.2 Companies 
Company Place 
Abbott GmbH & Co. KG Wiesbaden 
Abcam plc Cambridge, UK 
Acris Antibodies GmbH Hiddenhausen 
Adipogen AG Liestal, Schweiz 
Agfa Healthcare GmbH Köln 
A.Hatenstein GmbH Würzburg 
Alcan Packging Neenah Wiscosin 
Amersham Freiburg 
Applichem GmbH Darmstadt 
ASYS Hitech GmbH Eugendorf, Austria 
Axxora Deutschland GmbH Lörrach 
Bachem AG Budendorf, Switzerland 
Bayer AG Leverkusen 
BD Biosciences Heidelberg 
Biocat Heidelberg 
Bender &Hobein AG Zurich, Switzerland 
Biolegend Europe BV Uithoorn, Nederland 
Biomers Ulm 
Bio-Rad Laboratories GmbH München 
Biotechne (R&D, Tocris) Wiesbaden-Nordenstadt 
Biozym Scientific GmbH Oldendorf 
Braun Tuttlingen 
Cliper Life Sciences Rüsselsheim 
Carl Roth GmbH & Co.KG Karlsruhe 
Charles River Laboratories Sulzfeld 
Dako Deutschland GmbH Hamburg 
Dianova GmbH Hamburg 
Eppendorf AG Hamburg 
Fermentas GmbH St. Leon-Rot 
GE Healthcare Europe GmbH Freiburg 
Greiner Bio-One GmbH Frickenhausen 
Invitrogen GmbH Karlsruhe 
Kinesis GmbH Langenfeld 
Knick GmbH & Co.KG Berlin 
Lab instruments Deutschland GmbH Crailsheim 
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Lab & Vet Service GmbH Vienna, Austria 
Leica Microsystems Wetzlar 
LG Electronics Seoul, Korea 
Marienfeld GmbH & Co. KG Lauda-Königshofen 
Merck KGaA Darmstadt 
Messer Group GmbH Sulzbach 
Miltenyi Biotec GmbH BergischGladbach 
Minerva Biolabs Berlin 
MorphoSysAbD GmbH Düsseldorf 
New England BioLabs GmbH,  
(Cell Signalling) 
Frankfurt am Main 
Nikon GmbH Düsseldorf 
Olympus America Inc. Center Valley PA, USA 
Pall Life Sciences Dreieich 
Pan Biotech GmbH Aidenbach 
PE Applied Biosystems Waltham MA, USA 
PeproTech Germany Hamburg 
Peqlab Biotechnologie GmbH Erlangen 
Perbio Science Bonn 
Polysciences Europe GmbH Eppelheim 
Progen Biotechnik Heidelberg 
Promega GmbH Mannheim 
Qiagen GmbH Hilden 
Restek GmbH Bad Homburg 
Roche Diagnostics Mannheim 
Sanofi-Aventis Deutschland GmbH Frankfurt 
Santa Cruz Biotechnology, Inc. Heidelberg 
Sarstedt Nürnberg 
Serva Heidelberg 
Semperit AG Vienna, Austria 
Sigma-Aldrich Chemie GmbH Taufkirchen 
Sigma Laborcentrifugen GmbH Osterode am Harz 
Sony Corporation Tokyo, Japan 
SsniffSpezialdiäten GmbH Soest 
Stratec Biomedical AG Birkenfeld 
Synchem OHG Felsberg/Altenburg 
Systec GmbH Wettenberg 
Tecan Deutschland GmbH Crailsheim 
Thermo Fisher Scientific Inc. Walthham MA, USA 
Trevigen Inc. Gaithersburg, USA 
Vitaris AG Baar 
VWR International GmbH Darmstadt 
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Whatman International Ltd. Maldstone, UK 
Zentrallager Theoretikum Heidelberg 
 
2.1.3 Chemicals and reagents 
 
Product Product number, company 
Aceton #40143 Zentrallager Theoretikum 
Agarose #15510-027, Invitrogen 
Aluminium sulfate #192430050, Acros Organics 
Albumin Fraction V (BSA) #8076.2, Carl Roth 
Ammonium chloride #32205, Riedel-de Häen, Zentrallager 
Theoretikum (Heidelberg university) 
Aluminium sulfate #192430050, Acros Organics 
Aqua injection water #23114.01, Braun 
Boric acid #A3581,1000, Applichem 
Cell disassociation buffer #12151-014, GIBCO, Invitrogen 
CFSE #422701, Biolegend 
Chloramine-T-hydrate #857319-100G, Sigma-Aldrich 
Chlorpromazine #C8138, Sigma-Aldrich 
Coomassie brilliant blue R-250 dye #20278, Thermo Fisher Scientific 
DAPI #6335.1, Carl Roth 
Dithiothreitol (DTT) #D9779, Sigma-Aldrich 
Detection reagent ECL #32106, ECL western-blotting substrate 
pierce, Thermo Fisher Scientific 
4-Dimethylaminobenzaldehyd #39070, Fluka, Sigma-Aldrich 
Dimethyl sulfoxide #D2650, Sigma-Aldrich 
Di-sodium hydrogen Phosphate Dihydrate #A3567, 0500, Applichem 
DMEM #41966052, Gibco, Invitrogen 
DNA Exitus Plus #A7089, Applichem 
DNA marker 100 bp #T835, Carl Roth 
dNTP Mix #BIO-39044, Bioline 
DPBS #14190, Gibco, Invitrogen 
Dynabeads® sheep anti-rat IgG  #110.35, Invitrogen 
EDTA #E5134, Sigma-Aldrich 
Enhancer #01-1030, Peqlab 
Eosin G  #7089.1, Carl Roth 
Acetic acid #10296, Grüssing 
Ethanol #32205, Riedel-de Haen, Zentrallager 
Fast blue RR salt #F0500, Sigma-Aldrich 
FCS (Fetal Calf Serum) #P30-3302, Pan Biotech 
Formaldehyde #31245, Riedel-de Haen, Zentrallager 
G418 – Disulfate – solution, steril #A6798,0050, Applichem 
Gelatine 2 % #G1393, Sigma-Aldrich 
Gelatin sepharose #17-0956-01, Amersham, GE 
Healthcare 
Geneticin #30432, Sigma-Aldrich 
Urea #U5128, Sigma-Aldrich 
HBSS 10x #14185-045, GIBCO, Invitrogen 
Imidazole #104716, Merck 
Iodoacetic acid #35603, Thermo Fisher Scientific 
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Potassium chloride #A3582, 1000, Applichem 
Potassium hydrogen carbonate #P748, Carl Roth 
Potassium dihydrogen phosphate #1.04873.1000, Merck 
Potassium hydroxide #Z12038, Zentrallager Theoretikum 
Ketanest® Pfizer, pharmacy of hospital, 
Heidelberg university 
Sodium chloride 0.9 % #190/12606084, B.Braun 
Collagenase #17454, Seva 
β-Mercaptoethanol #444203-250 ml, Merck 
Methanol #32213-2.5L, Sigma-Aldrich 
2-Methylbutan #A1263, 1000, Applichem 
MgCl2 (PCR) #01-1030, Peqlab 
Micro BCA™ protein assay #23235, Thermo Fisher Scientific 
Milk pulver #T145.1, Carl Roth 
MES #M5287, Sigma-Aldrich 
Mowiol 4-88 reagent #475904, Calbiochem, Merck 
Sodium carbonate #A4332.1000, Applichem 
Sodium chloride #64026, Riedel-de Haen, Zentrallager 
Sodium citrate #S4641, Sigama-Aldrich 
Sodium deoxycholate #3484.1, Carl Roth 
Sodium fluoride #201154-5G-D, Sigma Aldrich 
Sodium dihydrate phosphate #106346, Merck 
Sodium dihydrate carbonate #106323, Merck 
Sodium hydroxide #30620, Sigma Aldrich 
Sodium nitrate #237213, Sigma Aldrich 
Sodium orthovanadate #S6508-50G, Sigma-Aldrich 
Sodium thiosulfate #S7026, Sigma-Aldrich 
N-ethylmaleimide #2251,0005, AppliChem 
Ni-NTA Agarose #R901-01, Thermo Fisher Scientific 
NP40 #ab142227, Abcam 
Opti-MEM #31985-062, Gibco, Invitrogen 
Penicillin/streptomycin #15140-122, Gibco, Invitrogen 
peqGOLD Trifast #30-2010, peqlab VWR 
Phenolphthalein #34607, Sigma-Aldrich 
Phenylmethylsulfonylfluoride (PMSF) #A0999,0005, AppliChem 
Pierce™NeutrAvidin™Agarose #29200, Thermo Fisher Scientific 
Polyinosinic-polycytidylic acid (plpC) #IAX-200-021-3005, Adipogen 
2-propanol #69595, Riedel-de Häen, Zentrallager 
Proteinase k #3115852001, Roche 
Propidium iodide #421301, Biolegend 
Puromycin #540411, Merck 
Redsafe #21141, Hiss Diagnostics 
Revertaid reverse transcriptase together with 
5x reaction buffer 
#EP0442, Fermentas 
Ribolock RNase inhibitor 
RNAzol RT 
#EO0381, Fermentas 
#R5433, Sigma 
HCl #Z-23-88, ZentrallagerTheoretikum 
SensiMix ™ capillary kit #QT405-01, Bioline 
Taq DNA-polymerase #01-1030, Peqlab 
Taq DNA-polymerase MPI for Biochemistry Martinsried 
Terminale deoxyribonucleotidyl transferase #16314015, Thermo Fisher Scientific 
Tissue-Tek #4583, O.C.T compound, Sakura, VWR 
MATERIAL AND METHODS 
24 
 
Tris #4855.2, Roth 
Tris-HCl #9090.3, Roth 
Triton X-100 #108603, Merck 
Tween 20 #9127.1, Roth 
TMB #613544, Merck 
Trypan blue 0.4 % #1525-061, Gibco, Invitrogen 
Trypsin-EDTA #25300, Gibco, Invitrogen 
Xylazine Hospital pharmacy, Heidelberg 
University 
         
2.1.4 Media, buffers and solutions 
Name  Components 
ACK-lyse buffer 4.15 g ammonium chloride / 0.5 g potassium-hydrogen 
carbonate /100 μl 0.5 M EDTA (pH=7.5) in 500 ml H2Od, steril 
filtration 0.22 μm, kept at 4°C until use 
Agar #15510-027, Invitrogen 
Agar gel 1.5 % - 2 % Agar in 1xTBE-buffer, heated in microwave, 2 μl 
Red Safe added and mixed well. Solution was poured 
carefully and used fresh 
Albumin fraktion V (BSA)  #8076.2, Roth 
αMEM   #22561, Gibco, Invitrogen 
Blocking buffer (ELISA) 3 % BSA in PBS-T 
Micro BCA™ protein 
assay 
#23235, Thermo Fisher Scientific  
Blocking buffer (ELISA)
  
3 % BSA in PBS-T  
cDNA Synthese kit iScript select, #170-8896, BioRad 
Cell dissotiation buffer #12151-014, GIBCO, Invitrogen 
CFSE, for cell staining Biolegend, dilution1:10000 / 1x 107cells 
Coomassie-staining 
solution 
Imperial protein stain (#24615, Pierce, Thermo Fisher 
Scientific), protein-gels were stained for 1h, destained with 
H2Od for >1h  
DAPI #6335.1, Roth 
Detection reagent #32106, ECL western blotting substrate, Pierce 
DMEM #41966052, Gibco, Invitrogen 
DMSO #D2650, Sigma-Aldrich 
DNA Exitus Plus #A7089, Applichem 
DNA-lyse buffer 100 mM tris (pH 8.5) / 200 mM NaCl / 5 mM EDTA (pH 8), 0.2 
% SDS, in 10 ml autoclaved H2Odd 
DNA-Marker 100 bp-DNA-ladder extended, #T835.1, Roth  
dNTPs #20-3012, Peqlab 
D-PBS  #14190, Gibco, Invitrogen 
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Dynabeads® goat anti-rat IgG, #110.35, Invitrogen, Protein G-beads 
#100.04D, Invitrogen 
Enhancer (PCR) #01-1030, Peqlab 
Ethidiumbromid 10 mg/ml, #2218.1, Roth 
FACS-buffer  2.5% FCS in D-PBS 
FCS #P30-3302, Pan Biotech 
Gelatine Sepharose 4B #17-0956-01, GE Healthcare  
Geneticin #10131027, Gibco, Invitrogen 
Heparin #H3149-25KU, Sigma Aldrich 
HEPES #15630-056, Gibco, Invitrogen 
Carbonate-buffer 
(ELISA) 
0.78 g Na2CO3 / 1.5 g NaHCO3  
in 500 ml H2Odd, pH 9.6, stored at 4°C (used for maximally 2 
months)  
Ketanest® Hospital pharmacy, Heidelberg university, Pfizer 
Luciferin #bc219, Synchem  
MgCl2 (PCR)   #01-1030, Peqlab 
Mowiol (Elvanol) 5 g Mowiol 4-88 Reagent, 20 ml PBS (pH 8), overnight rotation 
at RT. Addition of 10 ml Glycerin followed by incubation for 30 
min at 50°C in water. Centrifugation for 30 min / 5000 xg. 
Solution stored at -20°C 
Paraformaldehyd-
solution 4 % 
22.5 ml H2Odd was mixed with 5 μl 10 M NaOH at 60°C. 1 g 
Para-formaldehyde and 2.5 ml 10x PBS were added. Solution 
was allowed to cool down, pH adjusted at 7.4, and stored in 
aliquots at -20°C 
PBS (1x) 100 ml PBS (10x), in 1 L H2Od, stored at RT  
PBS (10x) 400 g NaCl, 58g Na2HPO4 / 10 g KH2PO4 / 10 g KCl in 5 L 
H2Od, pH 7.0, stored at RT  
Penicillin / Streptomycin #15140-122, Gibco, Invitrogen 
Sample buffer (DNA, 4x) 50 % glycerine in 4x TBE, with addition of bromphenol blue  
Propidium iodide #421301, Biolegend 
Proteinase-K-solution 20 mg/ml proteinase-K in H2Od 
Stopping solution 
(ELISA)  
0.5 M sulphonic acid (H2SO4) 
TaqMan® master kit
  
#04735536001, Roche 
Taq-reaction buffer #01-1030, Peqlab 
TBE (1x) 100 ml TBE (10x), in 1 L H2Od, stored at RT  
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TBE (10x) 108 g tris / 55.6 g boric acid / 4.65 g EDTA in 1 L H2Od, stored 
at RT  
TMB #613544, Merck 
Trifast™  peqGOLD, PeqLab 
Trypsin-EDTA  #25300, Gibco, Invitrogen 
Digestion solution 
(tumor) 
0.025 g collagenase NB4 / 0.05 % DNAse I 
Dilution buffer (ELISA) 1.5 % BSA in PBS-T 
Coating buffer (ELISA) 14.71 mM sodium carbonate 
35.71 mM sodium hydrogen carbonate 
Add up 500 ml millipore H2Odd 
DOC lysis buffer 2 % sodium deoxycholate 
20 mM tris-HCl, pH 8.8 
Proteinase inhibitor 1:100 
2 mM EDTA / 2 mM iodoacetic acid 
2 mM N-ethylmaleimide 
Wash buffer (ELISA) 100 ml PBS (x10), 0.5 ml Tween 20, 900 ml H2Od 
10X transfer buffer 29.2 g glycine, 58 g tris 
37.6 ml 10 % SDS solution in 1 L H2Odd 
Wash buffer Ni-NTA 3.45 g NaH2PO4, 29.22 g NaCl, 0.68 g imidazole 
PH 7.4 – 7.8 
Elution buffer gelatine 
sepharose 
4 M urea, 0.05 M tris in PBS (240 g urea, 6 g tris in 100 ml 
PBS, PH at 7.5, add H2Odd up 1 L) stored at RT 
Elution buffer Ni-NTA 50 mM NaH2PO4, 1M NaCl, 250 mM imidazole (for 50 ml aqua 
braun water add 0.345 g NaH2PO4+2.922 g NaCl+0.851 g 
imidazole, adjust PH to 7.4 – 7.8)  
Equilibration buffer for 
Gelatine Sepharose 
0.01 M sodium citrate and 0.005 M EDTA in PBS  
(for 100 ml 10x solution add 2.94 g sodium citrate and 1.86 g 
EDTA, PH 7.2). Solution stored at RT 
Running buffer 10x 
(SDS-PAGE) 
30.25 g tris, 144 g glycine and 10 g SDS in 1 L H2Odd 
 
2.1.5 Used materials 
Alcohol swab               #G602, Servopax 
Aluminium foil    #2596.1, Carl Roth  
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Cell culture bottles  #169900 25 cm2, #156800 75 cm2, #159926 
175 cm2, Nunc  
Cell culture plates  #150239 6-well-plate, #144530 24-well-plate 
Cells filter  #352360 100 μm cell strainer, BD Biosciences  
Centrifuge tubes  #188271 15 ml, #227261 50 ml, Greiner Bio-
One 
Chamber slides     #177445, Nunc  
Cover foil     #300001358, Tecan  
Cover-glass     #6101242, Marienfeld 
Cryo tubes     #123263, Greiner Bio-One 
Dialysis tube     #44145, Servapor, Serva 
Embedding molds    #64708955, Heraeus Kulzer GmbH  
Frisch foil  #59206, Zentrallager Theoretikum (University 
of Heidelberg)  
Glass capillaries qPCR    #04929292001, Roche  
Gloves      #3780872, Sempercare, Semperit AG  
Hamilton-pipette    #75 RN, 31/2“3/S, Hamilton 
Injection cannula  #304000, Microlance, 30G, BD Biosciences 
#302200 Microlance, 27G, BD Biosciences  
Macrosep     #OD100C36, Pall  
Microtiter plates    #439454 Maxi Sorp, Nunc  
Microvette #20.1288, 200 K3E (Blood plasma), Sarstedt  
Object-holder    #4951PLUS, Thermo Fisher Scientific  
Ointment for eyes and nose  #2182442, Bepanthen, Bayer  
Parafilm      #P-996, Alcan Packaging  
Pasteur pipettes    #197734230, Neo Lab 
PCR-reaction tubes    #711080, Biozym 
Petri dishes      #633171, Greiner Bio-One  
Pipette tips         #739296, 740290, Greiner Bio-One  
PVDF-membrane #RPN303F, Amersham Hybond-P, GE 
Healthcare  
Radiography films    #10595000 Structurix D4 DW, AGFA  
Reaction tubes     #72.706 1.5 ml 
Sephadex-columns #28-9180-07 PD MiniTRAP™ G-25, GE 
Healthcare  
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Serologic pipettes     (2, 5, 10 & 25 ml), Greiner Bio-One  
Steril filter  #SLGV033RS Millex GV 0.22 μm, PVDF-
membran, millipore  
Tubes   #55.1578, Polypropylene 12/75 mm, Sarstedt 
Whatman papers  #3030917 3MM CHR, Whatman International 
Ltd.  
2.2 Animal experimentation methods 
2.2.1 Animals 
In this work, only animals of the genus mus musculus (house mouse) were used. 
These were bred and kept in a pathogen-free facility (IBF-Heidelberg) during the whole 
period of the experiments. They were kept in a cage of polycarbonate with a size of 
360 cm in which up to 3 animals were placed using dust-free softwood granules (#LTE 
E-001, Lab & Vet service GmbH). The animals were fed exclusively with a pelleted 
sole diet (# V1166-341, sniff Spezialitäten GmbH), and kept in a temperature of (20-
24)°C and a relative humidity of (55-60)%. The animal were exposed to a diurnal cycle 
lasting 12 hours with lights on from (0700-1900) mid-european time (MEZ). The 
drinking water of the mice consisted of tap water. Thus, it could be ensured that the 
experiments always took place under standard conditions. All animal experiments were 
approved by the Animal Protection Commission of the regional council Karlsruhe and 
the application numbers are: 
- G-13/17 (the effect of matrix on tumor growth of human breast cancer) 
- G-34/19 (the effect of matrix on tumor growth of B16 melanoma) 
- G-127/15 (the role of EDA and EDB fibronectin in tumor metastasis) 
 
The immune deficient mouse strain used in these experiments was obtained from 
Charles Rivers. It is based on the CD1 strain (Caesarean Derived 1). These mice carry 
a mutation in the FOXN1 gene. Homozygous mice lack the thymus, which means that 
T lymphocytes cannot mature and thus they are immunodeficient. These 
immunodeficient mice are among the best characterized laboratory animals that offer 
the opportunity to study the behavior of human tumors in an experimental setting. B16 
melanoma was injected in immune competent mice that have C57BL/6 in their 
background. Therefore, the melanoma mouse line B16, which was obtained from a 
C57BL/6 mouse can be used. 
2.2.2 Anesthesia of laboratory animals 
Mice receiving intratibial injection were anesthetized by subcutaneous injection of 0.5 
µg/g medetomidine, 5 µg/g midazolam and 0.05 µg/g fentanyl. The surgical tolerance 
in this type of anesthesia lasts about 3 hours. Here too the cornea of the eye was 
protected from dehydration through use of the eye ointment. After surgery, anesthesia 
was reversed by administering a mixture of antagonists and pain control. This mixture 
consisted of 2 µg/g atipamezole, 0.412 µg/g flumazenil and 0.06 µg/g buprenorphine, 
and was injected subcutaneously. 
A mixture of ketamine (120 mg/kg body weight) and xylazine (16 mg/kg body weight) 
was injected into the mice intraperitoneally before radiography of the skeleton. 
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Anesthesia is adequate after 3-5 minutes, so that high quality X-ray images of the 
skeleton can be obtained. An eye ointment was applied (Bepanthen, Bayer, # 
2182442) to prevent drying of the eye cornea during anesthesia and subsequent loss 
of vision. The surgical tolerance can be tested by a lack of toe reflex and lasts up to 20 
minutes.  
 
2.2.3 Intratibial injection of human breast cancer cells 
The intratibial injection of human breast cancer cells is a xenograft model to transfer 
of human breast cancer cells into immune deficient mice. In this model, the mouse is 
firstly anesthetized and fixed under a binocular. Under deep anesthesia, a 1 cm long 
cut through the skin along the tibia is performed with a scalpel. The existing muscle 
layers are removed away to expose the tibia clearly.  Then with the help of a thin dental 
drill, two small holes are performed at a distance (4-5) mm and a diameter of 
approximately 0.2 mm through the bone cortex of the proximal tibia. Subsequently, the 
bone marrow is rinsed by a syringe filled with 1 ml DPBS and a 30 G cannula and the 
blood that is coming out from the holes is removed using a sterile cotton swap. Then, 
the cancer cells (1 x105 cells/5 µl DPBS) are injected using Hamilton pipette and the 
holes are closed immediately with surgical bone wax. After removing the rest of the 
wax and cleaning of the wound, the muscle and skin layer are sutured with an insoluble 
Supramid thread (Supramid, USP 5/0) with 2-3 stitches. The final closing of the wound 
was done using a spray plaster and the mouse is awakened by application of the 
subcutaneous antagonist injection. 
Following the intratibial injections, and after administering the antidote mixture that 
contains buprenorphine against pain, the mice received further injection of 
buprenorphine (temgesic, 0.05-0.1 mg/kg) every 4-6 hours for 3 days. Instead of 
continuing injections at night, buprenorphine was added to drinking water for pain 
therapy 0.3 mg/ml (2.5 ml/80 ml drinking water) at night for the next two nights after 
surgery. The last injection took place in the evening before changing the water to the 
mixture buprenorphine/water and was resumed the next morning when changing of 
the mixture buprenorphine/water to drinking water. This provided an adequate pain 
control. 
 
2.2.4 Bioluminescence imaging 
Since the human breast cancer cells have a luciferase construct, the tumor cells can 
be visualized in the organism by administration of luciferin which is the substrate of the 
luciferase that can convert the enzyme into light. This light emits in a range of (500-
700) nm with a maximum emission at 612 nm at 37°C and is able to penetrate the 
biological tissues. The measurement was carried out by (IVIS-100, xenogeny) in the 
clinical-experimental area of IBF (IBF, Maushotel, Im Neuenheimer Feld, building 347, 
69120 Heidelberg). To achieve that, the mice are anesthetized in an inhalation 
chamber which is connected to the imaging device and is supplied with the anesthetic 
gas isoflurane. A solution containing luciferin (150 mg/kg body weight) was 
administrated intraperitoneally. After five minutes of an intraperitoneal injection of 
luciferin, the mouse is placed under an isoflurane inhalation mask in a dark chamber 
on a table heated to 37°C. Since this device is provided with a sensitive camera which 
is located in the light chamber, the position, the number of tumor cells and the size of 
the tumor can be detected by performing ventral and dorsal measurement for each 
mouse. The mouse must be aligned so that the entire body is visible (objective distance 
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10 cm, camera position “field of view C”). The normal recording time is 1 minute with a 
medium capacity, however that is dependent on the size of the tumor. Therefore, the 
measurement was done for 1 minute and 2 minutes for each mouse. The system also 
takes additionally a photographic image of the mouse in order to localize the 
bioluminescence signal in the mouse. The software “live imaging” (version 2.5, 
xenogen) was used for quantification. It calculates the relative light unit (RLU) from the 
emitted light of region of interest (ROI). 
2.2.5 Radiography of bone lesions 
The osteolytic lesions which are caused by the tumor cells could be characterized by 
radiography. This was done by an X-ray machine at the immunology and serology 
institute of Heidelberg university (type 70025320, BIO-RAD). First, the mice were  
anesthetized with a mixture of ketamine and xylazine and then placed on the X-ray film 
so that the edges and the whole body of the mouse could be distinguished. The used 
voltage was 30 kV for 3 minutes. After measurement, the X-ray films were developed 
and scanned for the evaluation. The area, length and width of the osteolytic lesions 
were determined using the computer program “ImageJ”.  
 
2.2.6 B16 - Melanoma - animal experiment model 
In this model, mice were first anesthetized with Isoflurane and then 106 B16 melanoma 
cells in 100 µl PBS were injected subcutaneously into the left flank of the mouse. The 
same anesthesia was applied for tumor size measurement before start of treatment.  
 
 
2.2.7 Therapeutic treatment with peptides 
The peptides were provided by the biochemical core facility of Max Planck institute for 
Biochemistry in Martinsried. These peptides were isolated from the biomass or from 
synthetic raw mass using Nickel-columns that bind the preceding 6-HIS-tag 
(MKHHHHHH-) as described in 2.4.8. After confirmation of identity and concentration, 
the concentration was adjusted to 5 mg/ml using NaCl 0.9 % and following steril 
filtration aliquots were frozen at 80°C until use. In the breast cancer model peptide 
injections started at day 29 until day 39, with killing at day 40. In the melanoma model 
peptide injections started at day 7 until day 13, with killing on day 14. The injections 
were administered at a dose of 0.5 mg (100 l of a solution of 5 mg/ml) intraperitoneally 
daily at the same time of the day. In addition to the group receiving scrambled peptide 
a group only received 100 l NaCl 0.9 % administered daily intraperitoneally.  
 
pUR4 peptide which represents the functional upstream domain (FUD) of F1 adhesion 
molecule of Streptococcus Pyogenes and has the following sequence: 
KDQSPLAGESGETEYITEVYGNQQNPVDIDKKLPNETGFSGNMVETEDT 
The peptide consists of 49 amino acids and has a molecular weight of 5376.71 g/mol 
and an extinction coefficient of 0.54. 
 
The Scrambled peptide was as follows: 
EKGYSKPPVGNEGGDQVDEYDTMSQTKLEDEGNTLISPITFENATEQVN 
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pUR4 was further modified based on the literature [148, 151, 234] and the new 
modified peptide has the following sequence: 
GGKNTPLPSVYDIMTTVSGFEKEIDEEDQTGLQVGKTSNGAEETDPKANQNEY 
 
This new modified peptide includes two main motifs which mimics the ones in pUR4 
and can interact with 3FNI and 2FNI modules of fibronectin with high affinity. It consists 
of 53 amino acids and has a molecular weight of 5734 g/mol and an extinction 
coefficient of 0.52. 
The obtained data indicated that the modified peptide acts as a fibronectin 
polymerization inhibitor. Therefore, it was interesting to find out which part of this 
peptide is responsible for that effect. To achieve that, the modified peptide was divided 
into 3 individual peptides (A, B and C) which have the following sequences: 
A: GGKNTPLPSVYDIMTTV (17 amino acids) 
B: SGFEKEIDEEDQTGLQV (17 amino acids) 
C: GKTSNGAEETDPKANQNEY (19 amino acids) 
The next step was to further fractionate and modify the most efficient sequence and 3 
new peptides were further designed which have the following sequences: 
1: SGFEKEIDE 
2: EDTQTGLQV 
3: KEIDEEDQT  
All of the peptides were injected intraperitoneally at a dose of 0.5 mg in 100 l 0.9 % 
NaCl daily. 
 
2.2.8 Killing of the experimental mice 
The euthanasia of the experimental mice was carried out by cervical dislocation. After 
killing, the mouse was fixed and the tumors were isolated. A piece of tumor was 
cryopreserved on a Whatman paper and shortly sunken in isopentane, which was 
previously cooled in liquid nitrogen. Then the tumor was also kept shortly in liquid 
nitrogen in order to ensure the rapid freezing of the tumor. Finally, the tumors were 
frozen at -80°C.  
2.3 Cell biology methods 
2.3.1 Murine melanoma cell line B16-F10 
The murine B16-F10 melanoma cell line has been isolated from the skin of C57BL/6 
(H-2b) mice and is a highly invasive skin cancer cell line that leads to rapid tumor 
growth after its subcutaneous application in mice. This cell line is particularly suitable 
for using in anti-tumor therapeutic trials because of its easy administration, easy 
monitoring and its rapid growth. The tumor growth of this cell line is controlled by a 
variety of immune receptors and it has been reported that it is mainly associated with 
T cell-dependent growth [235]. 
2.3.2 Human breast cancer cell line MDA-MB-231B/luc+ 
The human breast cancer cell line MDA-MB-231B/luc + was previously isolated in 1973 
from a pleural effusion (fluid accumulation in the pleural cavity) of 51 years old 
caucasian woman at the M.D. Anderson Cancer Center in Houston, USA. They are 
adenocarcinoma cells originating from the mammary gland tissue. They are frequently 
used as a cancer research model because they tolerate culture conditions and adhere 
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well in-vitro. In these cells, the letters luc+ were added because a reporter gene for 
luciferase enzyme was transfected using a CMV promoter-controlled expression vector 
[236]. Since the vector contained a resistance gene against geneticin, following 
transfection cells are maintained in media containing this antibiotic. The letter B was 
added because they were developed to seek bone tissue for metastasis formation. To 
achieve this, cells were selected after four injection cycles in mice after each one, cells 
tumor cells were only isolated from bone metastases. The clone that is called “bone-
seeking clone” that grows exclusively in the bone was generated and by using it, it was 
possible to investigate bone lesion formation by breast cancer cells. 
2.3.3 Isolation of immune cells from tumors 
In order to characterize the immune cells of the tumors, each tumor was isolated and 
put in 1 ml digestion medium (DMEM + 1 mg/ml collagenase A + 0.05 % DNAse). After 
shaking in a thermostatic shaker for 45 minutes at 37°C, digested tumors were 
resuspended and passed through a 100 µm cell strainer. 
2.3.4 Depletion of immune cells from tumors 
Filtered cells (see 2.3.3) were resuspended in 1 ml DPBS. Magnetic protein G beads 
(Dynabeads, Invitrogen) were used. These beads bind all antibodies by their heavy 
chains. Beads were first washed with DPBS and then held on magnet (MACS®) in 
order to remove the liquid. This was followed by incubation with 5 µg antibody in 200 
µl DPBS for 30 minutes at room temperature (RT) in an electric shaker (30 µl of beads 
were used for about 1 x 107 cells). Beads were washed again with DPBS and the cells 
(1 x 107 cells in 1 ml DPBS) were added and incubated with the beads for 30 minutes 
at room temperature. Then, the beads with the cells were washed with DPBS 3 times. 
To obtain mRNA from the isolated cells, beads were exposed to 300 µl RNAzol with 
short vortexing.  
2.3.5 Determination of cell number 
For this purpose, a Casy-TT® cell counter was used. It is also used to characterize the 
size distribution, cells aggregation and the viability of the cells. A specific program 
could be created for each cell type. By using Casy®-Blue solution, the dead cells and 
debris could be distinguished from the healthy cells because they have a different flow 
behavior through the device and a different size.  
The measurements are carried out by pulling the cells through two lasers and 
determining the exact cell count, state of aggregation and the viability (%) averaged 
from three measurements.  
2.3.6 Passaging and preparation of tumor cells for in vivo injections 
In order to use cells that were of similar passages, the cells were passaged before the 
start of the experiments in high quantities and frozen in liquid nitrogen. From these 
frozen aliquots the cells were thawed and used fresh or passaged maximally twice. 
Thus, the cells used in the experiments originated from passages that were close to 
each other. For freezing, the cells were washed with DPBS and removed from the 
flasks with medium after 5 minutes incubation with 0.5 % trypsin-EDTA. Then, they 
were centrifuged and taken in freezing medium that consists of DMEM + 10 % FCS 
and 1 % DMSO and each 1 ml of suspension was put in cryotubes. Then, the tubes 
were frozen in isopropanol freezing chamber at -80°C which ensures that the cells are 
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frozen gently and slowly. After two days, the cells could be transferred to liquid 
nitrogen. 
 
For all in-vivo experiments, the tumor cells were thawed (3-5) days before the 
experiment. On the day before the in vivo injection, the cells were washed with DPBS 
and cultured with fresh medium without antibiotics. On the day of injection, the cells 
were washed again with DPBS and detached with 0.05 % trypsin-EDTA for 5 minutes 
at 37°C. The viability of the cells and the number were determined as described 
previously by Casy-TT® cell counter. For in vivo experiments, only cells showing 
viability higher than 90 % and an aggregation less than 1.3 were used. The required 
count of the cells for each mouse was calculated and then the cells were again 
centrifuged at 1500 rpm for 5 minutes and resuspended in DPBS for injection. Finally, 
the cells ready for injection were kept on ice under sterile conditions until injection. 
2.4 Protein biochemical methods 
2.4.1 Production of matrix lysates 
In order to investigate the extracellular matrix formed by cultured cells, the matrix was 
isolated based on its insolubility in sodium deoxycholate (DOC). The method had 
already been described but was slightly modified [237]. In brief, tumor cells were 
cultured in 48-well plates over a period of 2 days. Then, culture medium was removed 
and the cells were washed with DPBS. The cells were resuspended in 170 µl DOC 
lysis buffer per well and pressed three times through a 27 G needle to remove the 
genomic DNA and transferred into a 1.5 ml reaction tube. After centrifugation at 13000 
rpm for 17 minutes at 4°C, the supernatant was transferred to a new reaction tube, 
which represents the fraction soluble in deoxycholate, the doc sol (deoxycholate 
soluble, soluble in deoxycholate). The insoluble pellet is the doc insol (deoxycholate 
insoluble, insoluble in deoxycholate) which was resuspended in 29 µl SDS buffer. Both 
the isolated doc sol and doc insol fractions were stored at -20°C to be quantified by 
ELISA and the amount of matrix components corrected to total protein quantified using 
the BCA assay. 
2.4.2 Production of protein lysates for analysis of western blot or 
ELISA 
To obtain protein extracts from the tumors, a small (2 mm) piece was lysed in 300 µl 
protein lysis buffer and minced with the plunger of a 1 ml syringe. The mixture is then 
centrifuged at 12000 rpm for 10 min and the supernatant transferred to a new reaction 
tube. The samples were stored at -80°C until analysis.  
2.4.3 Protein concentration by Bradford-assay 
Micro BCA™ protein assay kit was used for determination of the protein content in 
protein lysates. The samples were diluted in Millipore water 1:400-1:1000 depending 
on the expected protein amount. The standard curve of BSA protein contains the 
following concentrations: 200, 40, 20, 10, 5, 2.5, 1, 0.5, ng/ml. 150 µl of prepared 
samples were added to 96 well-plate and then 150 µl of working solution as described 
in manufacture instructions (BCA protein assay kit, #23225, Thermo scientific). Finally, 
the plate was incubated for 2 h at 37°C and then according to the manufacturer’s 
instructions, the evaluation was carried out at wave length 562 nm in a microtiter plate 
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reader. For determination of standard curve and thus protein concentration, the 
Magellan V6.4 software was used. 
2.4.4 ELISA (Enzyme linked immunosorbent assay) 
Enzyme linked immunosorbent assay refers to a method that detects and quantifies of 
soluble proteins possible through the use of specific antibodies against these proteins. 
Detection of matrix fibronectin was achieved using a sandwich ELISA method in which 
the primary antibody to the molecule of interest was used in coating buffer to coat the 
plate overnight/4 °C and 50 µl was used in each well. The next day, after washing three 
times with PBS-T, the plate was blocked for one hour by blocking solution containing 
3 % BSA (Bovine serum albumin) in order to prevent unspecific binding. After that, the 
plate was washed three times with PBS-T. Samples were diluted with dilution buffer 
containing 1 % BSA. The dilution factor was a sample-dependent (conditioned media 
1:4, matrix 1:2). 50 µl of prepared samples were added to each well. A dilution series 
of standard protein and an internal control protein was also prepared and added to the 
plate in order to determine the exact concentration of fibronectin in the samples. The 
samples and the standards were incubated for 2 h RT to allow for binding to the primary 
antibody. Then the plate was washed with PBS-T and 50 µl of the secondary antibody 
against the desired protein was added. After 45 minutes of incubation, the plate was 
washed to remove the excessive antibody that was not bound to the protein of 
samples. Since the secondary antibody is conjugated to HRP, the successful binding 
could be visible by adding 50 µl of TMB substrate solution in each well. After 50 minutes 
of incubation at room temperature, the reaction was stopped by 50 µl stop solution 5M 
H2SO4. Finally, the plate was analyzed in a Tecan brand microtiter plate reader at the 
wave length 450 nm and the protein concentration could be calculated by the standard 
curve using the Magellan V6.4 software. 
2.4.5 Human and murine plasma fibronectin ELISA 
As clarified previously, the sandwich ELISA method was used for detection both 
human and murine plasma fibronectin.  Anti fibronectin (Sigma-Aldrich, #F3648) from 
Sigma 1:5000 was used as a primary antibody for both human and murine ELISA. 
Human plasma fibronectin previously purified from frozen human plasma using gelatin 
sephrose column was used as a standard. The standard curve of human plasma 
fibronectin contained the following concentrations: 2000, 1000, 500, 250, 100, 50, 25, 
12.5, 6.25, 3.125, 1.56 ng/ml. The following concentration were made from the 
purchased murine plasma fibronectin (Dunn): 4000, 2000, 1000, 500, 250, 100, 50, 25, 
12.5, 6.25, 3.125 ng/ml). Human plasma from a healthy donor was used as an internal 
control for human plasma fibronectin ELISA and aliquots from a pool of murine plasma 
obtained from 8 mice was used as an internal standard for murine fibronectin ELISA. 
The secondary antibody was a HRP-labeled anti-fibronectin (rabbit polyclonal) (at a 
dilution of 1:2000 for murine fibronectin ELISA and 1:5000 for human fibronectin 
ELISA).  
2.4.6 SDS gel electrophoresis 
The separation of proteins based on their molecular weight was performed using SDS 
sodium dodecyl sulfate polyacrylamide gel electrophoresis. Denaturation of the 
proteins and their binding with SDS creates a negative charge shell, which covers the 
charges of the amino acids and thus allows separation in correlation with the molecular 
weight [238]. To separate a protein solution by SDS gel electrophoresis, a 
polyacrylamide separating gel is prepared based on the plan in Table 2.4.6. After the 
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addition of APS (Ammonium persulfate solution) and TEMED (Tetramethyl 
ethylenediamine), the gel must be poured immediately and covered with isopropanol. 
After the separating gel has polymerized, the isopropanol is removed, the collecting 
gel is placed on the separating gel and a comb is carefully inserted without air bubbles 
into the chamber. Although the collection gel is solid, the gel can be kept wet and 
stored at 4°C or used immediately. The samples are mixed with 5x loading buffer and 
denatured at 95°C for 5 minutes. From each sample, 10-20 µl was applied to the gel. 
The electrophoresis was performed at a voltage of 100V for 60 minutes and then either 
stained with Coomassie staining solution for 10 minutes and washed with distilled 
water until the proteins are visible in the gel, or the proteins are transferred to a 
nitrocellulose membrane. 
 
 
 Separation gel, 10 ml, 10 % Stacking/collecting 
gel, 3 ml 5 % 
Deionized water 4.2 ml 1.8 ml 
30 % Acrylamid solution 3.3 ml 0.5 ml 
1.5 M Tris / HCl pH 8.8 2.5 ml - 
1.0 M Tris / HCl pH 6.8 - 0.8 ml 
TEMED 0.007 ml 0.003 ml 
10 % APS 0.1 ml 0.03 ml 
 
Table.2.4.6 Pipetting scheme for the preparation of separation and stacking/collection 
gel   
2.4.7 Western blot 
The proteins separated by SDS gel electrophoresis are transferred to a nitrocellulose 
membrane and then proteins can be detected on the membrane with the help of 
specific antibodies [238]. For the transfer of the proteins from the SDS gel to the 
nitrocellulose membrane, the semi-dry blotting method was used. For this purpose, 
four Whatman filter papers and a nitrocellulose membrane were cut to the size of the 
gel and placed in the transfer buffer. Two filter papers were placed on the anode of the 
semi-dry-blotter from peqlab, then the nitrocellulose membrane and the SDS gel and 
finally two filter papers. The sheets must lie on each other without air bubbles and then 
the cathode, which is located in the cover, is connected. The transmission of the 
proteins takes place at a constant voltage of 15 V for one hour. The membrane is 
sometimes cut based on the size of detected protein to allow for parallel blotting. The 
membranes are blocked with 5 % milk for one hour in order to get rid of unspecific 
protein binding. Membranes are washed with PBS-T and incubated with the primary 
antibody overnight at 4°C. The next day, the membrane is washed three times with 
PBS-T and incubated for one hour with a secondary antibody directed against the 
primary antibody and coupled with HRP (horseradish peroxidase) which can convert 
the luminal substrate into an oxidized form producing light. This light can be detected 
using autoradiography films (x-ray film # RF12 fuji Medical Super Rx, A. Hartenstein). 
To do that, the membrane is incubated with western blotting substrate (from Pierce), 
which is mixed 1:1 PBS-T and incubated for 2 minutes and then placed in a film 
cassette. In the dark room, the film is placed on the membrane and incubated for strong 
signals for 10-30 seconds and for weak signals for 2-5 minutes. The film in then 
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developed with AGFA type CP1000 development machine and finally evaluation is 
carried out using the freeware program ImageJ (Wayne Rasband, NH). 
 
The primary antibodies that were used are: 
- Fibronectin, Millipore, #ab2033, 1:5000, rabbit 
- GAPDH, Sigma-Aldrich, #G9545, 1:10000, rabbit 
- His-tag, Novagen, #70796-3, 1:1000, mouse 
 
The secondary antibodies 
- Goat anti-rabbit HRP, Dianova, #111-035-045, 1:10000 
- Goat anti-mouse HRP, BioRad, #170-6516, 1:10000 
2.4.8 Purification of peptides using a nickel-NTA column 
The peptides were produced at the core facility of the Max-Planck Institute for 
Biochemistry in Martinsried by Dr. Sabine Suppmann and Dr. Stefan Uebel. pUR4 was 
initially purified from biomass of transfected ClearColitm, which was supplied from 
Martinsried on dry ice. The isolation was done based on the presence of a His-tag 
sequence in the peptide (MKHHHHHH-). This His-tag forms a chelating complex with 
divalent nickel ions. Low imidazole concentrations allow unbound proteins to be 
washed off from the column, and by increasing the imidazole concentration, the target 
protein is eluted together with the His tag [239]. To perform this affinity 
chromatography, the biomass had to be mixed at least 1:1 with binding buffer and lysed 
on ice ten times for 10 seconds each using ultrasound sonication. Then, the lysate was 
centrifuged at 20000 rpm (SORVALL® RC-5B PLUS superspeed centrifuge, Thermo 
Fisher Scientific) for 30 minutes and about 30 ml supernatant is mixed with 1 ml Ni-
NTA agarose after washing of Ni-NTA agarose in equilibration buffer. The mixture is 
rotated overnight at 4°C. The next day, the peptides are detached in the so-called 
batch process from the column. To do that, the Ni-NTA lysate mixture is centrifuged 
for 3 minutes at 700 ×g and the supernatant is discarded. The nickel column was 
washed three times with 10 ml wash buffer. Then, the peptides were eluted for 4-5 
times with 2 ml elution buffer from the Ni-NTA agarose. The nickel column is 
regenerated using MES buffer and washed again with Aqua-pro-injection water. For 
storage, the column is stored in 20 % ethanol at 4°C. To purify the control peptide 
pUR4scr, 8 M urea had to be added to the binding buffer so that the peptide would not 
precipitate. The synthetic peptides were also produced so that they have a His-tag and 
were isolated using the same method. The benefit was the absence of endotoxins and 
the ability to refold the protein on the column to avoid precipitation. The sequences 
were as follows:  
pUR4: KDQSPLAGESGETEYITEVYGNQQNPVDIDKKLPNETGFSGNMVETEDT  
The His-tag consisted of MK and 6 histidines on the amino side.  
The scrambled peptide was: 
EKGYSKPPVGNEGGDQVDEYDTMSQTKLEDEGNTLISPITFENATEQVN.  
All peptides were concentrated using 1kD Macrosep columns and the buffer changed 
to 0.9 % NaCl. After sterile filtration, the quality of the rebuffered peptide was tested 
on  SDS protein gel and the concentration was confirmed by comparison to a standard 
curve and finally stored in -80°C 
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2.5 Molecular biology methods 
2.5.1 Detection of mycoplasma by PCR 
Mycoplasma are the smallest prokaryotes. Their diameter varies between 0.1-2 µm 
which enables them to pass the sterile filters with pore sizes around 0.22 µm. 
Contamination of cell cultures with mycoplasma is therefore common, but it is also 
difficult to detect. Because contamination affects experimental results, it is important 
to exclude it. To do that, both the supernatant of confluent cells and isolated DNA of 
these cells are tested for mycoplasma contamination by PCR. 
 
Amounts for one sample:    PCR-Program: 
 
H2Od (PCR grade) 15.3 μl  95°C   3 minutes 
10× reaction buffer             2.5 μl            95°C   30 s 
Primer/nucleotide-mix  2.5 µl  55°C   30 s   ×39 
Internal control DNA  2.5 µl  72°C   30 s 
Taq (5 U/μl)    0.2 µl  4°C    ∞   
 
Σ 23 μl 
 
23 µl master mix was used for each PCR reaction tube and 2 µl was added from the 
sample, H2O was used as a negative control, a positive control was added. 10 µl from 
each PCR product was mixed with 10 µl DNA sample buffer and analyzed on a 1.5 % 
agarose gel. Mycoplasma contaminated samples and positive control can be detected 
at 265-268 bp. The internal control shows the correct performance of PCR through the 
presence of a band at 191 bp. 
2.5.2 RNA isolation and the reverse transcription of RNA 
For analysis of mRNA expression, cells or tissues were dissolved in RNAzol (1 ml 
RNAzol / 1x107 cells or 1 mg tissue) and lysed. The samples were frozen at -80°C or 
used directly for RNA isolation. The isolation was done according to the manufacturer's 
protocol. In short, 0.4-fold volume (HPLC H2O) of RNAzol was added, mixed, incubated 
for 5-15 min at room temperature and centrifuged for 15 minutes at 12000 xg. The 
supernatant was transferred to a new tube and again 0.4-fold volume of 75 % ethanol 
was added. The samples were incubated 8 min at room temperature and centrifuged 
for 8 min at 12000 xg). The precipitated RNA was washed with 75 % ethanol and 
centrifuged for 3 minutes at 12000 xg). Finally, the isolated RNA was dissolved in 
RNase-free water (about 30 µl) and frozen at -80°C or used directly for cDNA synthesis 
in order to analyze mRNA by reverse transcription quantitative PCR. 
2.5.3 Flow cytometry analysis 
Flow cytometry is a technique that can group the cells accurately depending on their 
size and granularity as well as expression of various proteins using specific antibodies 
for both cell surface proteins or intracellular proteins. These antibodies are labeled with 
dyes that can be excited by different lasers and the resulting emission is converted by 
detectors into dots on a screen (Diva, BD Bioscience). In this work, LSRII from BD 
Bioscience was used. Tissues were isolated and 1x106 cells were suspended in 100 
µl FACS buffer and stained with the respective antibodies for 30 minutes at 4°C. 300 
µl of FACS buffer was added for washing and samples were centrifuged at 2400 rpm 
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for 5 minutes. The supernatant was discarded and the pellet was resuspended in 100 
µl FACS buffer and measured immediately using flow cytometry. Each cell is 
represented as a single point and can be viewed in a dot blot or histogram. Unstained 
cells or non-specific antibodies coupled with the same fluorescent dye (isotype control) 
can be used as negative controls. The evaluation of the data was carried out using the 
DIVA software from BD Bioscience. 
- The antibodies that were used for staining are as follows: 
- Anti CD45, pacific Blue, clone 30-F11, dilution 1:400, #103125, Biolegend. 
- Anti CD11b, Alexa flour 700, clone M1/70, dilution 1:1600, #101222, Biolegend. 
- Anti CD11b, FITC, clone M1/70, dilution 1:1600, #101205, Biolegend. 
- Anti F4/80, PE, clone BM8, dilution 1:400, #123110, Biolegend. 
- Anti Gr1, Alexa Flour, clone RB6-8C5, dilution 1:1600, #108420, Biolegend. 
- Anti Gr1, PE/Cy5, clone RB6-8C5, dilution 1:800, #108409, Biolegend. 
- Anti CD49e (integrin α5) (human), APC, clone NKI-SAM-1, dilution 1:100, #328012, 
Biolegend. 
- Anti-beta 2 microglobulin (human), PE, clone B2M-01, dilution 1:1600, #ab49424, 
Abcam. 
 
2.6 Histological methods 
2.6.1 Preparation of tumor sections 
The tumors were isolated and frozen with isopentane and liquid nitrogen and finally 
stored in -80°C. To make frozen sections of these tumors, a piece of each tumor was 
embedded using tissue-tek (# 4583, O.C.T. compound, Sakura). As soon as tissue-tek 
hardens, it becomes white and firm.  5-10 μm thick sections were made with the 
cryomicrotom (Cryostat CM 3050 of Leica). The chamber temperature was -25°C and 
the object temperature -12 to -15°C. The tumor slices were transferred to a microscope 
slide and dried for at least 30 minutes before being either immediately stained or stored 
at -20°C. 
2.6.2 Immunohistochemical staining of frozen sections 
The tumor sections were fixed with 4 % PFA (Paraformaldehyde) for 10 minutes at 
room temperature and then washed with 1x PBS. In order to reduce non-specific 
background staining of antibodies, the sections were blocked with 5% BSA in PBS for 
one hour at room temperature. Sections were then washed thrice with PBS and 
incubated with the primary antibody for one hour at room temperature. After washing 
for three times for 5 minutes with 1x PBS and staining with the secondary antibody for 
one hour at room temperature, the sections were washed tagain thrice with PBS for 5 
minutes and dried overnight. This was followed by mounting with Mowiol. In parallel to 
staining with the secondary antibody, nuclear staining was performed using DAPI 
1:10000 (Roth, #6335.1). Finally, the sections were kept at 4°C and the staining viewed 
and photographed using a fluorescence microscope (ECLIPSE Ti-E, Nikon, Heidelberg 
university hospital, institute for immunology and serology). The primary antibodies that 
were used for staining are as following: 
- Anti F4/80, e-Bioscience, #14-4801, 1:100, rat 
- Anti fibronectin, Millipore, #ab2033, 1:100 rabbit 
- Anti murine CD45, BD Pharmingen, #550539 1:100 rat 
The secondary antibodies are as following: 
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- Goat anti rabbit, Alexa fluor 555 Thermo, #A21430 1:500  
- Goat anti rat, Alexa fluor 594 Dianova, #112-585-062 1:500  
2.7 Statistical evaluations 
Statistical analysis of the experiments was done with the Microsoft Office software 
Excel 2010 and GraphPad Prism (V3, GraphPad Software Inc., San Diego, CA, USA). 
The statistical differences were evaluated using the two-tailed t-test for independent 
samples or the non-parametric Mann-Whitney test. Paired data were analysed using 
paired tests. Data are presented as mean and standard error of the mean (SEM). 
Significance was determined by a p value< or =0.05. Wherever relevant the exact p 
value was provided.
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3 RESULTS 
3.1 Confirming of the role of fibronectin of cancer cells in tumor 
growth 
The fibronectin produced by cancer cells plays a critical role in tumor growth, possibly 
through its interaction with the immune cells. Our group had already shown that 
deleting circulating fibronectin leads to decreased cancer growth [127], and a 
colleague had data suggesting that deletion of fibronectin in the cancer cells 
themselves also diminishes cancer growth, and that this effect might be due to a 
change in the immune response in the tumor [240]. To confirm the previous results of 
our group and expand on them, the breast cancer MDA-MB 231-B/luc+ cell line was 
used. 
3.1.1 Knocking down of fibronectin in MDA cells 
Normal human breast cancer MDA-MB231-B/luc+ line (MDA-CT) and those in which 
the endogenous fibronectin was eliminated by RNA interference (MDA-Kd) were 
cultured in vitro [241]. To identify the difference in fibronectin production between these 
two cell lines in particular the fibronectin of matrix, I used a specific protocol for matrix 
isolation which depends on its insolubility in sodium deoxycholate. ELISA experiments 
of matrix fraction (deoxycholate-insoluble fraction) show that the knockdown cells 
(MDA-Kd) produce significantly less fibronectin than the control cells (MDA-CT: 43±4 
vs. MDA-Kd: 30.2±2.2 ng/mg, p<0.01, n=38/31) (Figure 3.1.1). In support of these 
findings, western blot of conditioned media of MDA-CT and MDA-Kd cells also 
revealed a significant decrease of fibronectin in MDA-Kd conditioned media compared 
to the control media (figure3.1.1). 
 
 
 
 
 
 
 
 
 
Figure 3.1.1 Fibronectin expression of MDA-MB231 cells. (A) The fibronectin of knockdown 
tumor cells (MDA-Kd) showed a significant reduction in its expression (n=38/31). (B) 
Fibronectin was also detected in media by western blotting; densitometry (left) and 
representative of blots (right) showed a significant decrease in MDA-Kd media compared to 
MDA-CT media (n=3/3/3). 
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3.1.2 Induction of local bone metastasis 
To evaluate the effect of deletion of cancer cell fibronectin in vitro on cancer growth in 
vivo, both the normal MDA-CT line and the MDA-Kd line were injected intratibially into 
CD1nude control mice. 
3.1.3 Analysis of tumor growth 
Since the MDA tumor cells have a luciferase construct, tumor growth could be 
measured after 40 days of intratibial injection by Bioluminescence. Analysis of tumor 
growth showed a significant reduction in the growth of MDA-Kd cells compared to 
MDA-CT cells (MDA-CT: 7±1.1 x106 vs. MDA-Kd: 106±3x105 RLU, p<0.0001, n=29/19) 
(figure 3.1.3) 
 
Figure 3.1.3 Tumor growth of MDA-CT and MDA-kd cells. (A) There was a significant 
decrease in tumor growth of MDA-Kd cells compared to the growth of MDA-CT cells. (B) 
Bioluminescence image of tumor growth also confirms this reduction and the light emission of 
luciferase-expressing in tumor cells is represented by colored pixels (n=29/19).  
3.1.4 Radiographic analysis of osteolytic lesions 
Since the tumor cells also induce osteolysis in tibia after 40 days of tumor injection, it 
could be visualized by radiography in order to confirm the difference in growth between 
MDA-CT and MDA-Kd tumors. For the evaluation, the area, the length and width region 
were measured using the computer program image J.  
The analysis showed that the mean area of osteolytic lesion in MDA-CT tumors was 
7±1.02 mm2. The mean length 5.13±0.4 mm and the mean width 1.7±0.13 mm. A 
significant decrease in osteolytic lesion area of MDA-Kd tumors was detected (mean: 
3±0.6) mm2, (mean area CT vs. kd: p<0.01, n=20/17). In addition to the reduction in 
area, the length of osteolytic lesion of MDA-Kd tumors was also significantly reduced 
with an average 2±0.3 mm, (p<0.0001, n=20/17). 
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A significant decrease in the width of Kd osteolytic lesion was also detected at a mean 
of 1±0.0.12 mm, (p<0.0001, n=20/17) (figure 3.1.4) 
Figure 3.1.4 Size of osteolytic lesions of MDA-CT and MDA-Kd tumors by Radiography. 
(A, B and C) a radiographic analysis showed a significant reduction in the area, length and 
width of MDA-Kd tumors compared to the MDA-CT tumors. (D) X-ray images which show the 
reduction of osteolytic region in Kd tumors and that was consistent with the decreased tumor 
burden in bioluminescence imaging (n=20/17). 
3.1.5 Investigation of immune cells in MDA tumors 
Based on the findings of a prior member of the group, Sabrina Kraft [240], we evaluated 
the immune cells in these tumors by flow cytometer. Only macrophages (CD11b-
F4/80+) in Kd tumors increased compared to CT tumor (CT: 0.8±0.2 vs. Kd: 1.5±0.3 %, 
p<0.0001, n=29/19) (figure 3.1.5). 
 
Figure 3.1.5 Immune cells in the MDA-CT and MDA-Kd tumors. The immune cells in the 
tumor exclusively CD11b-F4/80+ showed a significant increase in Kd tumors compared to the 
control tumors (n=16/11). 
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3.2 Investigation of the effect of fibronectin accumulation 
inhibitor peptides in MDA human breast cancer model 
Fibronectin is an important component of the extracellular matrix and affects tumor 
progression through different mechanisms. As mentioned before the splicing pattern 
of its pre-mRNA patterns is deregulated in cancer [190]. Furthermore, fibronectin 
facilitates invasion by modifying ECM stiffness, affecting metalloproteinase production 
and protecting the tumor cells from immune system during circulation [109, 115, 223]. 
The previous work of our group has shown that prevention of fibril formation of 
fibronectin by pUR4 leads to reduction of collagen accumulation and fibrosis 
development and improves liver function [242]. Therefore, we asked whether inhibiting 
fibronectin accumulation by administering pUR4 leads to a decrease or slowing down 
of tumor growth. We tested this using two cancer cell lines which are murine melanoma 
cell line B16 and human breast cancer cell line MDA-MB 231/luc+. 
pUR4 is a polymerization fibronectin inhibitor derived from F1 protein which is the 
adhesion molecule of streptococcus pyogenes [151]. It contains 49 amino acids and 
has the following sequence: 
 
KDQSPLAGESGETEYITEVYGNQQNPVDIDKKLPNETGFSGNMVETEDT 
 
Recombinant scrambled peptide is similarly composed of 49 amino acids and has the 
following sequence: 
 
EKGYSKPPVGNEGGDQVDEYDTMSQTKLEDEGNTLISPITFENATEQVN  
3.2.1 Investigation of the effect of recombinant pUR4 and its 
Scrambled peptide on fibronectin of MDA cells in vitro 
Recombinant pUR4 and its control peptide were produced, purified and tested in vitro 
on cultured MDA cells. The effect of these recombinant peptides on the matrix was 
assessed after 72 hours. The fibronectin content was determined by human fibronectin  
ELISA and recombinantpUR4 diminished significantly fibronectin in the matrix fraction 
(deoxycholate in-soluble fraction) as shown by ELISA of the matrix (pUR4 treated cells: 
19±2 vs. Scrambled peptide treated cells: 31.4±6 ng/mg, p<0.05, n=22/17), (pUR4 
treated cells: 19±2 vs. MDA-CT: 43±4 ng/mg, p<0.0001, n=22/38). These results were 
comparable with the values of matrix measured by ELISA in MDA-Kd cells (MDA-Kd: 
30±2 vs. pUR4 treated cells: 19±2 ng/mg, p<0.0001, n=31/22) (figure 3.2.1). 
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Figure 3.2.1 Recombinant pUR4 decreases matrix accumulation of MDA-CT cells in 
vitro. pUR4 deceases the fibronectin in matrix of MDA cells by ELISA (n=38/31/22/17). 
 
3.2.2 Investigation of the effect of recombinant pUR4 on MDA tumor 
growth in vivo 
The next step was to determine whether the preventing of fibronectin polymerization 
by delivery of pUR4 could diminish the tumor growth in mice. Therefore, an intratibial 
induction of breast cancer cells was carried out and the in vivo experiments were 
designed as following (figure 3.2.2A): 
- The duration of each experiment is 40 days. 
- Tumor growth is monitored weekly and also after treatment by bioluminescence. 
- On day 28 the mice start receiving 0.5 mg of peptides for ten days. 
- Radiography is done before and after treatment 
On day 40, the mice are euthanized; tumors are isolated and digested for immune 
staining. 
 
 
Figure 3.2.2A. Schedule of in vivo experiment MDA module.  
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Analysis of tumor growth by bioluminescence measurement before and after of 
peptides injection showed that the rate of increase of tumor growth in pUR4 treated 
mice was significantly lower after treatment compared to Scrambled treated mice and 
control mice (day 39: CT: 8.364x106±1 x106 RLU vs. pUR4: 4.6 x106±1.013 x105 RLU, 
p<0.05, n=32/20), (pUR4: 4.549x106±1x106 RLU vs. Scrambled: 9.4x106±2.44x106 
RLU, p<0.05, n=20/10) (figure 3.2.2B). 
Figure 3.2.2B Tumor growth before and after of recombinant peptides injection. The 
detected photon emission was significantly reduced in mice in which the pUR4 was applied 
compared to the control groups (A and B) (n=32/20/10). 
3.2.3 Investigation of pUR4 entry into MDA tumors 
As shown previously, recombinant pUR4 slowed down of MDA tumor growth. 
Therefore, the further question was raised whether pUR4 could be detected in tumor 
lysates in order to confirm its effect on tumor. The administrated pUR4 and Scrambled 
contain poly histidine tag sequence which forms of six histidine residues at the N-
terminus of each peptide, therefore the presence of these peptides in the tumors could 
be confirmed by detection of this poly-histidine sequence which has the expected mass 
about 15 kDa. That was done by western blot of protein tumor lysates using anti-
polyhistidine-tag antibody. The blots of protein lysates of tumors ensured that the 
systemically administrated peptides could reach the tumors and perform its effect 
(figure 3.2.3).  
Figure 3.2.3 pUR4 and Scrambled peptides enter the tumor after application. The western 
blot analysis of the tumor lysates which were treated with peptides showed the His-tag 
contained in the peptides and as a consequence the respective peptides were in the tumors. 
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3.2.4 pUR4 decreases fibronectin content of MDA tumors 
The fibronectin content of MDA tumors which were treated with recombinant peptides 
was also assessed by ELISA and corrected to the total protein content. Less fibronectin 
was significantly detected in recombinant pur4 treated tumors compared to the 
pUR4scr treated tumors (pur4 treated tumors (pUR4 treated tumors: 234±32% vs. 
Scrambled: 403±58 ng/mg, p<0.05, n=8/7). No difference was observed in pUR4 
treated tumors compared to the control tumors (p=ns, n=8/7) (figure 3.2.4). 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.4 Fibronectin content in recombinant treated tumors. There was a significant 
decrease in pUR4 treated tumors compared to Scrambled treated tumors but not to the control 
tumors (n=7/8/7). 
 
3.2.5 Radiographic analysis of MDA tumors before and after of 
recombinant peptides injection  
X-ray images were taken before and after peptide injection. Due to the significant 
advantage of pUR4 injection in slowing down of tumor growth that was shown by 
bioluminescence, it was also important to investigate whether this effect could be 
confirmed by radiography. The average area, length and width of osteolytic lesions in 
pUR4 treated mice upon injection were significantly less than the Scrambled treated 
mice and control mice (area: CT: 7±1.016 mm vs. pUR4: 4±0.7 mm, p<0.05, n=20/17), 
(area: Scrambled treated group: 8.61±1.365 mm2 vs. pUR4 treated group: 4±0.7 mm, 
p<0.05, n=7/17), (length: CT: 5± 0.4 mm vs. pUR4 treated group: 3.3±0.4 mm, p<0.01, 
n=20/17), (length: Scrambled treated group: 5±0.5 mm vs. pUR4 treated group: 
3.3±0.4 mm, p<0.05, n=7/17), (width: CT 1.7±0.13 mm vs. pUR4 treated group: 
1.21±0.1 mm, p<0.01, n=20/17), (width: Scrambled treated group: 2±0.2 mm vs. pUR4 
treated group: 1.21±0.1 mm, p<0.001, n=7/17) (figure 3.2.5). 
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Figure 3.2.5 Radiographic analysis before and after of recombinant peptides 
application. The average area, length and width of the osteolytic lesions were statistically 
significantly reduced upon pUR4 treatment compared to the control groups (n=20/17/7). 
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3.2.6 Investigation of immune cells in MDA tumors treated with 
recombinant peptides 
In order to investigate whether the immune cells are enrolled in slowing down of tumor 
growth by pUR4 treatment, immune cells in these tumors were analyzed by flow 
cytometry in parallel with control tumors. There were no significant differences in total 
immune cells or monocytes (p=ns, n=11/18/8). The granulocytes and myeloid derived 
suppressor cells showed a significant decrease in pUR4 and Scrambled treated tumors 
compared to the control tumors (CD45+Gr1+ %) (CT: 4.318±1.92 vs. pUR4: 1.111±0.17 
%, p<0.05, n=11/18), (CD11b+Gr1+ %) (CT: 4.236±1.9vs. pUR4: 1.07±0.18 %, p<0.05, 
n=11/18). However, the subpopulation CD11b-F4/80+ showed a distinctive increase 
but not significant in pUR4 treated groups compared to the control groups (figure 
3.2.6). 
Figure 3.2.6 Analysis of immune cells in MDA tumors treated by recombinant pUR4. 
There were no significant differences in total immune cells (A), monocytes (B) or macrophages 
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(E) and (F) of tumors. The granulocytes (C) and myeloid suppressor cells (D) showed a 
significant decrease in pUR4 and Scrambled treated tumors compared to the control (D) (p=ns, 
n=11/18/8). 
3.2.7 Investigation of cancer and stromal cells in MDA tumors treated 
with recombinant peptides 
It is widely known that the stromal cells undergo changes in the presence of cancer 
cells and play a role during initiation, progression and metastasis of cancer. Therefore, 
it was interesting to determine how pUR4 might affect stromal cells. Their percentage 
could be evaluated by flow cytometry, however there was no difference in stromal cells 
between groups (p=ns, n=11/18/8). That was also confirmed using qPCR to evaluate 
the relative composition of cancers after depletion from immune cells (using geneticin 
expression, which quantifies the amount of cancer cells. Thus, recombinant pUR4 
affects neither stromal cells nor cancer cells (figure 3.2.7) 
Figure 3.2.7 Analysis of cancer cells and stromal cells in MDA tumors treated by 
recombinant peptides. No difference was found in cancer cells neither by flow cytometry nor 
by geneticin mRNA expression. There was also no significant change in stromal cells 
(n=11/18/8).  
The previous data indicate that recombinant pUR4 as a fibronectin polymerization 
inhibitor peptide could diminish fibronectin accumulation of MDA cancer cells in vitro, 
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slowdown of tumor growth in vivo, trend to increase of macrophages exclusively the 
sub-population CD11b-F4/80+ and to decrease significantly of myeloid derived 
suppressor cells MDSCs. However, no effect could be obtained on total stoma and 
cancer cells. 
3.3 Evaluation of the effect of synthetic peptides in MDA tumors 
In order to investigate whether there is a difference in effect between the recombinant 
and synthetic pUR4 and also to further understand clearly its mechanism and 
especially the involvement of immune cells in its activity, pUR4 and its control peptide 
pUR4scr were synthesized at Max Planck Institute of Biochemistry in Martinsried and 
tested in vitro and in vivo on human breast cancer cells. 
3.3.1 Investigation of the effect of synthetic pUR4 and its scramble 
on fibronectin of MDA cells in vitro 
As shown in the figure, fibronectin ELISA confirmed the effect of pUR4 on fibronectin 
accumulation in breast cancer cells in vitro  and the synthetic scramble caused also 
further reduction in fibronectin content (CT: 462.5±33.84 vs. pUR4: 250.9±25.17 
ng/mg, p<0.001, n=32/12); (pUR4: 250.9±25.17  vs. Scrambled: 473.5±51.87 ng/mg, 
p<0.001, n=12/6) (figure 3.3.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1 Synthetic pUR4 decreases fibronectin accumulation of MDA cells in vitro. 
fibronectin quantified in total cell lysate of MDA cells in vitro by ELISA after 72 hours induction 
of pUR4 was significantly less compared to the control (n=32/12/6). 
3.3.2 Investigation of the effect of synthetic pUR4 and its scramble 
peptide in MDA cells in vivo 
To further investigate the effect of synthetic peptides sequence on tumor growth, MDA 
tumors which were injected intratibially were treated with these peptides and compared 
to the control tumors. pUR4 kept slowing down of MDA tumor growth and that was 
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reproducible compared to the recombinant version (Scrambled: 1x107±1.8x106 RLU 
vs. pUR4: 6.73x106±1x106 RLU, p<0.05, n=16/20). (figure 3.3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.2 Analysis of tumor growth before and after of synthetic peptides injection. 
In comparison with control group, a statistically significant reduction in tumor growth was 
obtained in mice received of pUR4 and the first modified peptide (n=16/20). 
3.3.3 Evaluation of fibronectin content of MDA tumors treated with 
synthetic peptides 
The effect of these peptides on fibronectin of MDA tumors should also directly be 
observed. Therefore, human fibronectin ELISA of the total protein lysates of treated 
tumors was done. Treatment by scrambled peptide did not affect the fibronectin 
content of MDA tumors compared with the control tumors. The tumors which were 
treated by synthetic pUR4 slightly reduced the fibronectin of MDA tumors compared to 
the control ones (p=ns, n=3/3/3) (figure 3.3.3).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.3 Fibronectin content in MDA tumors treated with synthetic peptides.  
ELISA of MDA tumors showed no significant difference among groups (n=3/3/3). 
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3.3.4 Radiographic analysis of MDA tumors treated with synthetic 
peptides 
In order to find a difference in osteolytic lesions among groups before and after 
treatment with the synthetic peptides, x ray analysis was done for the MDA tumors as 
described previously. No difference could be obtained among groups in the area, 
length and width of osteolytic lesions after the treatment with the synthetic peptides 
(p=ns, n=15/15/11) (figure 3.3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.4 Radiographic analysis of osteolytic lesions before and after of synthetic 
peptides injection. The average area of osteolytic lesions was slightly reduced compared to 
the control group (B) (n=15/15/11). 
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3.3.5 Evaluation of immune cells of MDA tumors treated with 
synthetic peptides 
To better understand the impact of peptides on the immune response of MDA tumors 
and as a consequence the tumor growth, mice injected intratibial tumors and treated 
with synthetic peptides were euthanized and immune cells of tumors were analyzed by 
flow cytometry. Leukocytes, monocytes, granulocytes and myeloid derived suppressor 
cells showed a little decrease in treated tumors but without significance (p=ns, 
n=18/20/9). The macrophages especially the subpopulation CD11b-F4/80+ showed a 
slight increase in pUR4 treated group compared to the control group (p=ns, n=18/20) 
(figure 3.3.5). 
 
Figure 3.3.5 Analysis of immune cells in MDA tumors treated with synthetic peptides. 
No significant difference between groups was obtained in immune cells analyzed by a flow 
cytometry (n=18/20/9). 
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3.3.6 Evaluation of cancer and stromal cells of MDA tumors treated 
with synthetic peptides 
Flow cytometry analysis of digested tumors was also done to investigate the effect of 
synthetic peptides on the stromal and cancer cells. No difference among groups was 
detected in stromal cells or cancer cells (p=ns, n=18/20/9) (figure 3.3.6). 
 
Figure 3.3.6 Analysis of stromal cells and cancer cells in MDA tumors treated with 
synthetic peptides. No difference was observed between groups in the percentage of stromal 
or cancer cells as analyzed by flow cytometry (A and B) (n=18/20/9). 
3.4 Effect of pUR4 in immunocompetent mice 
Since the peptides were tested in immune deficient mice where T cells are absent, it 
was important to further characterize their effect in immunocompetent mice in order to 
improve our understanding about their mechanism and also to investigate whether T 
cells are involved in their effect.  
3.4.1 Investigation of the effect of recombinant pUR4 and its 
scramble peptide on fibronectin of B16 melanoma cells in vitro 
Recombinant pUR4 and its control peptide were tested in vitro on cultured B16 
melanoma cellsthat has been isolated from the skin of C57 / BL6 (H-2b) mice. It is a 
highly invasive skin cancer cell line that can be applied subcutaneously under the 
epidermis of mice [243]. The effect of these recombinant peptides on the matrix was 
assessed after 72 hours. The fibronectin content was determined by fibronectin murine 
ELISA and recombinant pUR4 decreased significantly matrix fibronectin compared to 
the control groups (CT: 291.3±37.34 vs. pUR4: 185.2±25.24 ng/mg, p<0.05, n=23/21) 
(figure 3.4.1). 
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Figure 3.4.1 Recombinant pUR4 decreases matrix accumulation of melanoma cells in 
vitro. pUR4 deceases the fibronectin in melanoma matrix by ELISA (n=23/21/21). 
3.4.2 Investigation of the effect of synthetic pUR4 and its scramble 
peptide on fibronectin of B16 melanoma cells in vitro 
As the synthetic versions of peptides were tested on MDA cancer module, it was critical 
also to further characterize their effects on B16 cancer module. The effect of synthetic 
version of pUR4 and its scramble was also tested in vitro on B16 melanoma cells. The 
fibronectin content of total protein lysates of B16 melanoma cells was assessed by 
ELISA after 72 hours of peptides induction. No significant difference was observed 
among groups as shown in figure (3.4.2) (p=ns, n=12/12/12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.2 Effect of synthetic peptides on fibronectin accumulation of B16 melanoma 
cells in vitro. No significant effect was observed on fibronectin accumulation of B16 
melanoma cells after 72 hours of synthetic peptides induction as assessed by ELISA 
(n=12/12/12) 
 
 
     CT          pUR4    Scrambled 
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3.4.3 Investigation of the effect of synthetic peptides on B16 tumors 
growth in vivo 
To further investigate the effect of pUR4 on melanoma cells in vivo, subcutaneous 
injection of murine B16 melanoma cells was carried out and the in vivo experiment was 
designed as shown in figure (3.4.3A) 
 
At the age of 5 weeks mice were injected subcutaneously with 1x106 B16 melanoma 
cells. Tumor growth was evaluated starting day 4 every other day. On day 8, mice were 
briefly anesthetized by isoflurane and tumors were measured using calipers. 
Treatment was then started using peptides (0.5 mg daily) for 5 days. 
 
Figure 3.4.3A Schedule of in vivo experiment B16 model 
 
After sacrificing the mice, the length, the width and the weight of tumors were 
determined and compared to the ones of before treatment. The width of pUR4 treated 
tumors was significantly reduced compared to the scrambled treated group 
(Scrambled: 0.4±0.03 vs. pUR4: 0.3±0.02 mm, p<0.05, n=18/18) (figure 3.4.3D). 
Interestingly, there was no effect of synthetic pUR4 on the width of B16 tumors. 
However, a significant reduction was observed in the weight of pUR4 treated tumors 
compared to the control and scrambled treated tumors (CT: 124±20 vs. pUR4: 56±11.5 
mg, p<0.05, n=16/18), (Scrambled: 111±26 vs. pUR4: 56±11.5 mg, p<0.05, n=18/18) 
(figure 3.4.3E). 
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Figure 3.4.3 Tumor length, width and weight of B16 melanoma before and after of 
synthetic peptides treatment. There was a significant reduction in the width and the weight 
of pUR4 treated tumors compared to the control tumors (D and E) (n=16/18/18).  
 
3.4.4 Effect of the synthetic pUR4 on the immune cells of B16 tumors 
Since the fibronectin affects the immune response, it was important to investigate how 
pUR4 could affect the immune cells in B16 tumors. Analysis by flow cytometry of 
digested tumors showed that inhibition of fibronectin polymerization by synthetic pUR4 
administration results in a significant difference in leukocytes (CD45+: CT: 17.34±1.7 
vs. pUR4: 26±1.3 %, p<0.05, n=16/18), monocytes (CD11b+: CT: 7±0.6 vs. pUR4: 
10±1.2 %, p<0.05, n=16/18), granulocytes (CD45+Gr1+: CT: 4±0.3 vs. pUR4: 6.7±1.2 
%, p<0.05, n=16/18), myeloid derived suppressor cells (CD11b+Gr1+: CT: 3.45±0.3 vs. 
pUR4: 5.5±0.9 %, p<0.05, n=16/18), myeloid derived suppressor cells (CD11b+Gr1+) 
and macrophages (F4/80+: CT: 9.5±0.9 vs. pUR4: 14.4±0.6 %, p<0.0001, n=16/18). 
Macrophages and especially the sub-population (CD11b-F4/80+) showed a significant 
reduction in pUR4 treated tumors compared to scrambled and control treated tumors 
as well (F4/80+: Scrambled: 11.7±0.8 vs. pUR4: 14.4±0.6 %, p<0.00, n=18/18), 
(CD11b-F4/80+: CT: 2.8±0.7 vs. pUR4: 5±0.8 %, p<0.05, n=16/18) (Scrambled: 3±0.4 
vs. pUR4: 5±0.8%, p<0.05, n=18/18) (figure 3.4.4 E and F). 
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Figure 3.4.4 Effect of synthetic pUR4 on immune cells of B16 tumors. There was a 
significant increase in the number of leukocytes (CD45+) (A), monocytes (CD11b+) (B), 
granulocytes (CD45+Gr1+) (C), myeloid derived suppressor cells (CD11b+Gr1+) (D) and 
macrophages (F4/80+ and especially CD11b-F4/80+) (E and F) in pUR4 treated tumors 
compared to control tumors (n=16/18/18). 
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3.4.5 Effect of the synthetic pUR4 on cancer and stromal cells of B16 
tumors 
Stromal cells play a prominent role in tumor microenvironment. Therefore, it was 
important to find out the effect of synthetic pUR4 delivery on total stromal cells of B16 
tumors. B16 cancer cells were pre-stained using e-flour before injection in order to 
enable the analysis of fibronectin polymerization inhibitor effect on stromal and cancer 
cells by flow cytometry. Stromal cells were evaluated from the CD45- cells after 
excluding of cancer cells. Treatment by pUR4 did not affect cancer cells. A significant 
decrease was observed in the percentage of stromal cells in pUR4 treated tumors 
compared to control tumors (CT: 77±2 vs. pUR4: 69±2 %, p<0.01, n=16/18) (figure 
3.4.5). 
 
Figure 3.4.5 Effect of synthetic pUR4 on B16 melanoma cells and stromal in B16 tumors. 
No difference was obtained in cancer cells among groups (p=ns, n=16/18/18) (A). A significant 
reduction was obtained in stromal cells (which were taken from the live cells after exclusion of 
immune cells (CD45+) and e-flour stained B16 melanoma cells) in pUR4 treated tumors 
compared to control tumors (n=16/18). 
3.5 Evaluation of modified pUR4 effect on MDA cells 
Based on the previous functional binding studies of pUR4 [148, 151, 234], new 
modified peptide was designed and tested on MDA cells. The new modified sequence 
includes two main motifs which mimics the ones in pUR4 and can interact with 3FNI 
and 2FNI modules of fibronectin with high affinity. 
These synthetic peptides were tested in vitro on human breast cancer cells MDA-CT, 
the unexpected results were that not only pUR4 but also its new modified peptide 
diminished significantly fibronectin accumulation of MDA-CT cells as quantified by 
ELISA (CT: 46.8±4.2 vs. modified: 19.12±1.14 ng/mg, p<0.0001, n=36/30), (CT: 
46.8±4.2 vs. pUR4: 25±2.4  ng/mg, p<0.05, n=36/19), (pUR4: 25±2.4 vs. modified: 
19.12±1.14ng/mg, p<0.001, n=19/30) (figure 3.5).  
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Figure 3.5 The synthetic modified peptide decreases Fibronectin accumulation of MDA 
cells in vitro. Fibronectin assessed in matrix fraction of MDA cells in vitro by ELISA after 
induction of the synthetic modified peptide was significantly less compared to the control 
(n=36/19/30). 
3.5.1 Evaluation of modified synthetic peptides in vivo 
In vivo experiments using synthetic peptides not only confirmed the results of in vitro 
but also showed that the new synthetic modified peptide causes a decrease in tumor 
growth. However, the synthetic pUR4 showed the same effect on tumor growth as the 
recombinant one (pUR4: 9.13x106±1.6x106 RLU vs. modified: 2.4x106±7.5x105 RLU, 
P<0.01, n=6/6), (CT: 11x106±1.7x106 RLU vs. modified: 2.4x106±7.5x105 RLU, p<0.01, 
n=17/6) (figure 3.5.1). 
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Figure 3.5.1 Analysis of tumor growth before and after of synthetic peptides injection. 
In comparison with control group, a statistically significant reduction in tumor growth 
was obtained in mice received synthetic modified peptide and slight decrease was 
detected in pUR4 treated tumors (A and B) (n=17/6/6). 
3.5.2 Evaluation of fibronectin content in MDA tumors treated with 
synthetic modified peptide 
In order to find out the effect of the new modified peptide on the fibronectin 
accumulation in MDA tumors, western blot of the total protein lysates of treated tumors 
was done in parallel with the total protein lysates of Kd tumors to also further compare 
the fibronectin content of these tumors with the fibronectin of treated tumors. Treatment 
by new modified peptide decreased significantly the fibronectin content of MDA tumors 
compared with the control tumors and was less than the fibronectin content of Kd 
tumors. The tumors which were treated with synthetic pUR4 also slightly but not 
significantly decreased the fibronectin of MDA tumors compared to the control ones 
(figure 3.5.2).  
Figure 3.5.2 Fibronectin expression of MDA tumors treated with the second synthetic 
modified peptides. Fibronectin of MDA tumors which were detected by western blotting; 
destinometry (A) and representative of blots (B) showed a significant decrease in MDA tumors 
treated with the second modified peptide compared to the control tumors. 
3.5.3 Radiographic analysis of MDA tumors treated with the 
synthetic modified peptide 
Besides to the bioluminescence, radiographic images of the mice were also obtained 
as an additional evidence of the peptides effect. The analysis showed that the average 
area and width of osteolytic lesions in-mice injected with the synthetic peptides were 
slightly reduced compared to the control group but without significance (p=ns, 
n=15/5/5) (figure 3.5.3). 
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Figure 3.5.3 Radiographic analysis of osteolytic lesions before and after of synthetic 
modified peptide injection. The average area and width of osteolytic lesions was slightly 
reduced compared to the control group (B and F) (p=ns, n=15/5/5). 
 
3.5.4 Characterization of immune cells in MDA tumors treated with 
the synthetic modified peptide 
The immune cells of these tumors were also further analyzed by flow cytometry and 
no significant reduction was detected in leukocytes, monocytes of treated groups 
compared to the control group (p=ns, n=18/6/6). Since the granulocytes and myeloid 
derived suppressor cells strongly expanded in cancer, it was also critical to 
characterize them and they were slightly decreased in treated tumors but without 
significance compared to the control group (p=ns, n=18/6/6). The macrophages 
showed non-significant reduction but the sub-population CD11b-F4/80+ which tended 
to be increased after recombinant pUR4 treatment exclusively showed a significant 
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increase in treated groups compared to the control group (CT: 1±0.14 % vs. modified: 
2.7±0.4 %, p<0.0001, n=18/6), (CT: 1.033±0.14 % vs. pUR4: 1.8±0.4 %, p<0.05, 
n=18/6) (Figure 3.5.4).  
 
Figure 3.5.4 Analysis of immune cells in MDA tumors treated with the synthetic modified 
peptide. There was no difference in leukocytes (CD45+) (A), monocytes (CD11b+) (B), 
granulocytes (CD45+Gr1+) (C), or myeloid suppressor cells (CD11b+Gr1+) (D). A significant 
increase was observed in macrophages and exclusively the sub-population (CD11b-F4/80+) 
(F) (n=18/6/6). 
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3.5.5 Characterization of cancer and stromal cells in MDA tumors 
treated with the modified synthetic peptides 
Total cancer cells were also quantified in these digested tumors and a slight reduction 
in modified peptide treated group was obtained compared to the pUR4 treated group 
(p=ns, n=6/6). It was also surprising that the stromal cells modified peptide treated 
tumors were significantly increased compared to the control tumors (CT: 38±2.3 % vs. 
modified: 50±7 %, p<0.05, n=18/6) (figure 3.5.5). 
Figure 3.5.5 Analysis of cancer and stromal cells in MDA tumors treated with the 
synthetic modified peptide. No difference was observed in cancer cells among groups (A) 
and a significant increase in stromal cells (B) was observed by flow cytometry in modified 
treated tumors compared to the control ones (n=18/6/6). 
3.6 Investigation of the effect of modified peptide in B16 
melanoma cells 
Based on the effect of the synthetic modified peptide in decreasing of MDA tumor 
growth, it was interesting to investigate its effect in another cancer model which is B16 
melanoma cells. The schedule of the in vivo experiment is the same one shown in 
figure (3.4.3A). 
3.6.1 Investigation of the effect of synthetic modified peptide on 
fibronectin of B16 melanoma cells in vivo 
1 million B16 melanoma cells were injected into immune competent mice in order to 
further investigate the effect of T cells presence on development of treated tumors. 
Tumor growth is monitored by daily examination and peptides were injected daily for 5 
days after 7 days of tumor cells injection. Subsequently, the mice were euthanatized 
and the tumors were removed. The tumor size was determined by a caliper and the 
tumor weight using a sensitive scale. There was a reduction in tumor weight in the 
pUR4 and modified peptide treated mice compared to the controls (p<0.05, 
n=13/13/13/13) (figure 3.6.1E). The width and length of pUR4 and modified peptide 
treated tumors did not show any significant difference compared to the control and 
scramble treated tumors (p=ns, n=13/13/13) (figure 3.6.1B and D). 
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Figure 3.6.1 Tumor length, width and weight of B16 melanoma before and after of 
modified peptide treatment in immune competent mice. After 12 days of melanoma 
injection including peptides treatment for the last 5 days, there was a significant reduction in 
tumor weight (E). No difference was obtained in the length and width of treated tumors 
compared to the control ones (B and D) (n=13/13/13).  
 
3.6.2 Effect of the synthetic modified peptide on the immune cells of 
B16 tumors in immune competent mice 
In order to investigate whether the immune cells are responsible for diminished tumor 
growth, the tumors were analyzed by flow cytometry after digestion. A significant 
increase in leukocytes (CD45+: CT: 15.2±2.5 vs. pUR4: 24.7±1.7 %, p<0.05, n=8/8), 
monocytes (CD11b+: 7±1 vs. pUR4: 9.5±0.6 %, p<0.05, n=8/8) and macrophages 
(F4/80+: CT: 8±1.3 vs. pUR4: 13.2±0.6 %, p<0.05, n=8/8) were detected in pUR4 
treated tumors compared to the control ones (figure 3.6.2A, B and E). In modified 
peptide treated tumors, granulocytes (CD45+Gr1+) and myeloid derived suppressor 
cells (CD11b+Gr1+) were significantly decreased compared to control and pUR4 
groups (CD45+Gr1+: CT: 4.4±0.6 vs. modified peptide: 2.6±0.4 %, p<0.05,n=8/8), 
(CD45+Gr1+: pUR4: 4.4±0.3 vs. modified peptide: 2.6±0.4 %, p<0.05, n=8/8), 
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(CD11b+Gr1+: CT: 4.4±0.6 vs. modified peptide: 2.6±0.4 %, p<0.05, n=8/8), 
(CD11b+Gr1+: pUR4: 4.4±0.3 vs. modified peptide: 2.6±0.4%, p<0.05, n=8/8) (figure 
3.6.2C and D). A significant increase was observed in macrophages subpopulation 
with pUR4 (CD11b-F4/80+) (pUR4: 4±0.5 vs. modified peptide: 1.7±0.3 %, p<0.001, 
n=8/8) in modified peptide tumors compared to pUR4 treated tumors (figure 3.6.2F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.2 Immune cells in B16 tumors treated with synthetic modified peptide in 
immune competent mice. In B16 tumors, there was a significant increase in the number of 
leukocytes (CD45+) (A), monocytes (CD11b+) (B) and macrophages (F4/80+) (E) in pUR4 
treated tumors compared to the control ones. A significant decrease was also detected in the 
percentage of granulocytes and myeloid derived suppressor cells in synthetic modified peptide 
treated tumors compared to the control ones (C and D) (n=8/8/8).  
3.6.3 Effect of the synthetic modified peptide on B16 melanoma cells 
and stromal cells of B16 tumors in immune competent mice 
It was important to characterize these populations after treatment in B16 tumors. Since 
the B16 cells were previously stained with e-flour which could be seen in Alexa 647 
channel, they could be differentiated by FACs analysis. No significant difference was 
obtained in B16 cancer cells and stromal cells among groups (p=ns, n=8/8/8/8). No 
significant difference was obtained in B16 cancer cells among groups (figure 3.6.3A 
and B). 
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Figure 3.6.3 B16 melanoma cells and stromal cells in B16 tumors of immune competent 
mice treated with synthetic peptides. No significant difference was obtained among groups 
in B16 cancer cells and stromal cells (n=8/8/8). 
3.7 Investigation of the fractions of the modified synthetic 
peptide in vitro 
The previous data indicate that the modified peptide acting as a fibronectin 
polymerization inhibitor peptide could diminish fibronectin accumulation of MDA cancer 
cells in vitro and decreased tumor growth in vivo without affecting the immune 
response which was seen with pUR4. Therefore, it was interesting to find out which 
part of molecule is responsible for these effects. To achieve that, the modified peptide 
was divided into 3 individual peptides, synthesized in parallel with the original 
sequence of pUR4 and its scrambled peptide and tested in vitro on MDA cells for 72 
hours. 
Fibronectin content of matrix was assessed by ELISA and as shown in the figure, the 
peptide B which represents internal sequence of modified peptide diminished 
significantly fibronectin accumulation compared with the control cells and that was 
more than peptide A and peptide C (CT: 73.33±11 vs. peptide A: 46±8.152 ng/mg, 
p<0.05, n=14/21), (CT: 73.33±11  vs. peptide B: 38.2±4.5ng/mg, p<0.01, n=14/24), 
(CT: 73.33±11 vs. peptide C: 49±3.8 ng/mg, p<0.05, n=14/18). Treatment of the cells 
with 1mM tri-fluoroacetate was done in parallel as a control and its toxic effect killed 
the cells and reduced significantly the fibronectin more than the other groups compared 
with the control cells (CT: 73.33±11 vs. TFA: 26±8.2 ng/mg, p<0.01, n=14/11) (figure 
3.7A). 
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Figure 3.7A investigation the effect of the fractions of synthetic modified peptide on 
fibronectin accumulation of human breast cancer cells in vitro. The middle fraction 
(fraction B) of the synthetic modified peptide was the best one in the inhibition of fibronectin 
accumulation of human breast cancer cells. 
The synthetic modified peptide has functional domains in comparison to those of 
pUR4. It includes the SGF fragment which mimics the sequence in pUR4 that interacts 
with 3FNI. The sequence DEEDQT in the synthetic modified peptide also mimics EDT 
which was confirmed to interact with 2FNI with high affinity [244-246]. Depending on 
the literature mentioned previously, pUR4 and its modified peptide especially the 
fraction B were further fractionated, modified and 3 new peptides were designed and 
tested in vitro on MDA cells.  
Human fibronectin ELISA was assessed for total protein lysates after 72 hours of 
peptides induction. Peptide (1) was the best one in an inhibition of fibronectin 
accumulation of human breast cancer cells compared to the control cells (CT: 
462.5±33.84 vs. peptide (1): 350.9±46 ng/mg, p<0.05, n=32/18) (figure 3.7B). 
 
Figure 3.7B investigation the effect of the synthetic modified short peptides on 
fibronectin accumulation of human breast cancer cells in vitro. The sequence (1) reduced 
significantly the fibronectin accumulation of human breast cancer cells compared with control 
as shown by ELISA of the total protein lysates (n=32/18/18/18/12/14/15). 
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3.8 Cytokines expression of MDA tumors 
Most recent findings confirm the involvement of the inflammatory cytokines in tumor 
progression but at the same time it is so complex and need to be further characterized. 
Therefore, it was important to explore the link between their expression and the 
different cancer groups to increase our understanding of peptides mechanisms in order 
to be introduced as a new approach for cancer treatment. Since the peptides could 
alter the immune response in tumors which normally leads to the change of cytokines 
expression, it is interesting also to assess the cytokines expression in treated tumors. 
Arginase-1 has a tumor growth promoting effect in which it supports the M2 
macrophages. Firstly, I detected the expression of Arg-1 in CD11b+ cells which were 
isolated from MDA-CT and MDA-Kd tumors and 5 tumors in each group were pooled 
together. Arg-1 expression was reduced in Kd tumors compared to the control tumors. 
The expression of this cytokine was also assessed in total treated tumors and a 
significant decrease was observed in recombinant pUR4 treated tumors compared to 
the control (CT: 2±0.8x10-3 vs. pUR4: 0.004±0.002 x10-3, p<0.05, n=2/3) and a slight 
decrease but without significance was obtained in the synthetic pUR4 and modified 
treated tumors compared to the control (p=ns, n=3/3/2) (figure 3.8) 
 
Figure 3.8 Analysis of Arg-1 expressions in MDA tumors. A decrease in its expression was 
detected in CD11b+ cells of Kd tumors compared to control tumors (A). A significant reduction 
was detected in recombinant pUR4 tumors (B) (n=2/3). A slight decrease in the tumors treated 
with the synthetic modified peptide without significance (C) (n=3/3/2). 
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3.9 Immunohistochemical staining of MDA tumors 
Immunohistochemical staining of frozen sections of MDA tumors for fibronectin 
confirmed the results of ELISA as shown in the figure (3.9A) (fibronectin in red). Since 
the flow cytometry results were not clear enough to outline how the tested peptides 
could affect the non-malignant part of tumor microenvironment and especially the 
leukocytes and macrophages, it was necessary to investigate these populations in the 
frozen MDA sections of different tested groups by immunohistochemical staining. As 
shown in the figure (3.9A) by immune fluorescence, the administration of pUR4 and 
the synthetic modified peptide reduced the fibronectin content of tumors and that was 
consistent with the diminished fibronectin content of kd tumors where the endogenous 
fibronectin of cancer cells was knocked down. On the other hand, 
immunohistochemical analysis of frozen sections of tumors for leukocytes (CD45+ 
cells) clarified better the role of injected peptides in the immune response of tumors as 
the evaluation of these cells in pUR4 treated tumors revealed a significant increase 
compared with the Scrambled treated tumors and that was also consistent with the 
leukocytes values in kd tumors compared to control tumors(CT: 273±29 vs. kd: 760±34 
cells per mm2, p<0.0001, n=3 tumors/group, at least 3 sections in each group), (pUR4: 
624 ±42 vs. Scrambled: 429±65.6 cells per mm2, p <0.05, n=3 tumors/group, at least 
3 sections in each group). The frozen sections of MDA tumors were also stained for 
macrophages (F4/80+ cells) and the kd tumors, pUR4 and synthetic modified treated 
tumors showed a significant increase in macrophages compared to the control tumors 
(CT: 532±27.3 vs. kd: 815±36 cells per mm2, p<0.0001, n=3 tumors/group, at least 3 
sections in each group), (CT: 532±27.3 vs. modified: 857.7±90.04 cells per mm2, 
p<0.0001, n=3 tumors/group, at least 3 sections in each group), (CT: 532±27.3 vs. 
pUR4: 987±40.6 cells per mm2, p <0.0001, n=3 tumors/group, at least 3 sections in 
each group), (kd: 814.8±36 vs. pUR4: 987±40.6 cells per mm2, p<0.01, n=3 
tumors/group, at least 3 sections in each group) (figure 3.9A). 
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Figure 3.9 A Immunohistochemical staining of MDA tumors for fibronectin (fibronectin 
in red). The treatment with pUR4 and the synthetic modified peptide resulted in a decrease in 
fibronectin content in the tumor as shown by immune fluorescence (n= 3/group and at least 3 
sections for each tumor, bar=50 µm) 
 
Figure 3.9B Immunohistochemical staining of MDA tumors for fibronectin (fibronectin 
in red). The treatment with pUR4 and the synthetic modified peptide resulted in a decrease in 
fibronectin content in the tumor as shown by immune fluorescence (n= 3 / group and at least 
3 sections for each tumor, bar=50 µm). 
 
Figure 3.9C Evaluation of macrophages in MDA sections by immune fluorescence. 
Analysis of stained MDA sections for F4/80+ cells revealed a significant increase in Kd,  pUR4 
and synthetic modified treated tumors compared to the controls. A summary of the data is 
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shown in (B) as number of cells/mm2 and the representative images of the groups are shown 
in A (bar=50µm). 
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4 DISCUSSION 
4.1 Effect of tumor-cell-fibronectin on tumor growth 
4.1.1 Knock down of fibronectin in MDA-MB-231 cells 
The successful knock down (Kd) of fibronectin by RNA interference in breast cancer 
cell line has already been performed in our group and I was able to confirm this by 
ELISA of matrix fibronectin in Kd cells where it was diminished by 30% compared to 
the control cells. The low degree of deletion of fibronectin in Kd cells could be due to 
the fact that the cells were transfected more than 10 years ago and that some cells lost 
the promoter and thus, they were still able to produce fibronectin. However, the in vivo 
experiments in which these Kd cells were injected intratibially into immune deficient 
nude mice confirmed a decrease in cancer growth when using Kd cells. This was 
consistent with previous findings of our group, group, and is at least in part due to a 
decrease in angiogenesis due to the diminution of fibronectin in the tumor [240, 241, 
247] 
4.1.1.1 Effect on the growth of MDA-MB-231B / luc + - breast cancer cells 
Loss of endogenous fibronectin production by the tumor cells was confirmed by ELISA 
in vitro and the effect of this loss evaluated in vivo using the intratibial model of cancer 
lesion induction. The decrease in growth in this model is consistent with the results 
previously obtained in our group and the work of Anja von Au [127], where she showed 
that the deletion of circulating fibronectin led to a decrease in cancer growth due to 
diminished VEGF and blood vessel formation. Because of the high concentration of 
fibronectin found in several tumors, it was interesting to investigate the role of 
fibronectin in tumors. Tumor growth of Kd tumor cells in CT mice was significantly 
diminished compared to CT tumor cells in Alb-cKO mice in which circulating fibronectin 
was deleted using the albumin promoter attached to cre-recombinase in fibronectin 
floxed mice. The growth of MDA-CT tumor cells in Alb-cKO mice was also significantly 
less then the growth of both cells in CT mice but the growth of MDA-Kd cells was even 
more pronounced. This suggests that despite the decrease of fibronectin to the same 
degree in loss of circulating fibronectin and loss of cancer fibronectin there is an 
additional factor that limits the growth in Kd tumors. Possibly the immune cell 
composition. 
In work from our lab, Stephanie Rossnagl and Sabrina Kraft had found that the 
production of EDA-containing fibronectin leads to a change in the behavior of myeloid 
cells expressing CD11b against tumors [220]. Since the MDA-breast cancer cell line 
produces mostly EDA-fibronectin as was shown by Anja von Au, it is possible that the 
absence of EDA fibronectin also affects the immune cells in the tumors.  Since the 
immune response in the tumors can have an important impact on their growth, we 
analyzed the characteristics of the immune cells using the two cell lines producing 
fibronectin (CT) and the one lacking it (Kd) by flow cytometry. There was an increase 
in immune cells of myeloid lineage, with an increase in CD11b-F4/80+ of almost 50% 
in the MDA-kd tumors. The effect of loss of endogenous fibronectin on the immune 
cells was also confirmed by immunohistochemistry of frozen MDA sections which 
showed a significant increase in immune cells (CD45+ cells) and this increase was due 
to the significant increase of macrophages (F4/80+ cells) in the MDA-kd tumors by 
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immune histochemistry confirming the findings generated by flow cytometry. It should 
be noted that macrophages can be generated from CD11b+ cells [248]. This suggests 
that EDA-fibronectin might also play a role within the tumor itself in modulating the 
immune cell differentiation. Therefore, it seems that the loss of endogenous fibronectin 
of cancer cells leads to increase infiltration of immune cells into the tumor and that this 
effect contributes to a decrease in cancer growth. These findings are in line with the 
previous findings of our group. 
4.2 Modulation of fibronectin of cancer cells using a bacterial 
peptide 
As described previously, fibronectin has a variety of roles in several steps of tumor 
development. It mediates cell adhesion, migration, and proliferation. It is responsible 
for angiogenesis of tumors and affects metastasis formation [127]. Based on the 
previous finding in our group that the inhibition of fibronectin accumulation by 
application of a small peptide can improve liver function and reduce liver fibrosis [242], 
we decided to evaluate the effect of this peptide in cancer. The hypothesis is  that the 
decrease in fibronectin accumulation will lead firstly to decreased growth as was seen 
with the deletion of circulating fibronectin and also to an increase in the immune 
reaction against cancer as was suggested by the absence of EDA-fibronectin in 
osteoblasts in the bone marrow and the increase in immune cells in Kd tumors. As 
described previously, pUR4 represents part of an adhesion molecule (part of the 
functional upstream domain (FUD) of F1 adhesin molecule) of Streptococcus 
pyogenes. It consists of 49 amino acids. It belongs to a class of adhesions termed 
MSCRAMMS (Microbial Surface Components Recognizing Adhesive Matrix 
Molecules) which are known to bind specifically to fibronectin. because of pUR4 ability 
to prevent fibronectin polymerization, it was widely used as a tool in many biomedical 
studies to investigate the involvement of fibronectin in several processes such as 
vascular remodeling and angiogenesis [225, 249, 250]. It was reported that the F1 
domains can bind to the soluble and matrix fibronectin suggesting that binding sites 
are expressed in both forms of fibronectin [251, 252] by means of integrin 51 which 
has a function in fibronectin assembly and v3 integrin which is involved in the 
formation of focal contacts that are required for the assembly of fibronectin fibrils [253]. 
Several forms were evaluated: recombinant, synthetic and individually modified 
peptides in two cancer models which are human breast cancer cells MDA cells and 
melanoma murine cancer cells B16.  
 
4.2.1 pUR4 inhibits fibronectin accumulation of human breast cancer 
cells in vitro and reduces cancer growth in vivo 
The extracellular matrix has a complex and a dynamic structure that it is deposited, 
remodelled and degraded in order to maintain the tissue homeostasis. Many of 
previous studies have already reported the role of dysregulation of extracellular matrix 
in cancer development. The extracellular matrix consists of several of molecules, 
however because of its many functions, our group focuses on fibronectin. Although 
collagen seems to be involved in a variety of pathological processes, the presence of 
fibronectin is needed for the collagen accumulation [254] and that was confirmed in 
vitro and in vivo by our group. Furthermore, our group has already shown that the 
deletion of circulating fibronectin which is produced by liver cells leads to suppression 
of angiogenesis by decreasing VEGF concentrations and thus diminishing tumor 
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growth using the breast cancer MDA cells [127]. Based on the previous findings, the 
question arose whether the modulation of fibronectin could lead to smaller breast 
cancer tumors. Because fibronectin plays a crucial role in many steps of cancer 
development, it was interesting to find out whether reducing of fibronectin content in 
tumors can affect significantly the tumor growth. Treatment of human breast cancer 
cells for 72 hours with pUR4 in vitro reduced the fibronectin of matrix as assessed by 
ELISA. These data were consistent with the previous in vitro data showing that 
inhibition of fibronectin polymerization decreases the accumulation of fibronectin in the 
ECM [210, 225, 242], and suggest that pUR4 might have an effect on breast cancer 
growth. The in vivo findings confirmed the inhibitory role of pUR4 on fibronectin 
accumulation which led to a slowing of the growth of MDA tumors. These results were 
comparable with the effect of knocking down of endogenous fibronectin on tumor 
growth. This was similar to what was already confirmed by our group in a liver fibrosis 
model [242]. Importantly, the immune response against cancer cells was also changed. 
The macrophages which play a fundamental role in the tumor microenvironment either 
by supporting a proinflammatory response and diminishing its growth (M1 cells) or by 
inhibiting the immune response and thus indirectly promoting cancer growth (M2) [255-
257]. The immune cells mostly consisting of macrophages were increased in tumors 
of mice treated with pUR4. This could be due to increased leukocytes infiltration 
through the vessel wall [225].  However, no effect could be observed on the cancer 
and stromal cells. On the protein levels, pUR4 diminished the total fibronectin content 
of tumors compared to the control tumors. All of the previous findings confirm the 
importance of fibronectin polymerization and accumulation in the development of 
cancer. Therefore, targeting fibronectin could be a key for improving cancer treatment.  
4.2.2 pUR4 diminishes tumor growth of murine B16 melanomas 
B16 murine melanoma cells are commonly used for studying tumor growth because 
they share similarities with the human melanoma [258]. These cells represent a good 
model for studying the immune response, because it has already been shown that 
myeloid suppressor cells (CD11b+Gr-1+ cells) promote proliferation in the B16 
melanoma cells [259]. These cells often [260] interact with T cells, therefore they 
offered the opportunity to study the role of T cells, in particular T cell suppression 
induced by myeloid suppressor cells. We used immunocompetent mice in order to 
determine the effect of the peptides on myeloid-T-cell-mediated immune response. 
Melanoma cells were injected subcutaneously into the left flank of the mouse and after 
7 days of melanoma injection in immune competent mice in order to allow the tumors 
to reach a measurable size, tumor size was measured. The synthetic peptides affected 
the tumor growth of MDA in immune deficient mice and B16 in immune competent 
mice. The flow cytometry analysis of immune cells of tumors however replicated some 
of the changes seen in MDA tumors treated with pUR4 and in MDA-Kd tumors. It is 
clear that an effect on immune cells is seen in the absence of fibronectin in tumors 
after treatment with pUR4. Whether this can be exploited in the fight against cancer is 
not clear. 
As shown in figure (4.2.2), binding studies performed by others had already shown that 
none of the synthesized N- and C-terminal peptides were able to inhibit fibronectin 
polymerization to a degree similar to the pUR4 with its 49 Amino acids. Binding affinity 
studies confirmed that loss of the 7 N-terminal amino acids eradicates the inhibitory 
effect. Furthermore, the lack of only 6 amino acids on the C-terminal also resulted in a 
100-fold decrease in inhibition. Interestingly, the 7 N-terminal amino acids did not have 
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any inhibitory effect. Therefore, it seems that the sequence within pUR4 is important 
for inhibiting fibronectin fibril formation [151, 234] 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.2. Schematic representation fibronectin binding F1 domains of streptococcus 
pyogenes and individual FUD derived peptides [151]. Representation of F1 adhesion 
molecule and its functional domains besides to the truncated sequences of the 
functional upstream domain (FUD). Reproduced and modified from [151] 
It has been reported that deletion of fibronectin from cultured cells leads to loss 
collagen fibrils [261]. Furthermore, the fibronectin-collagen interactions prevent the 
collagen degradation [262]. Therefore, the decrease in fibronectin probably also 
diminishes collagen accumulation. It could be shown that as collagen accumulates, it 
contributes to the stiffness and progression of cancer [118]. It is possible that 
preventing fibronectin and indirectly collagen accumulation also contributed to the 
suppression of cancer growth in tumors treated with pUR4. This highlights the 
importance as well as the complexity of matrix in cancer.  
4.2.3 The effect of the modification of pUR4 in vivo and in vitro 
pUR4 both in recombinant and synthetic form prevented fibronectin accumulation in 
vitro and in vivo. We decided to modify this sequence in order to become an even 
stronger effect and if possible, stimulate the immune response against cancer.  
It was previously reported that all of the fibronectin-binding MSCRAMMS include the 
VETEDT sequence and analysis of different sequences of pUR4 showed that this last 
six amino acids sequence of pUR4 is crucial for the high binding affinity to fibronectin 
[252, 263]. The general conclusion that has been characterized from the binding 
studies that presence of 7-N terminal amino acids, the 6-C-terminal amino acids and 
the entire sequence are fundamental for the optimal inhibitory activity [151]. Regarding 
the binding interactions, the optimal blocking of fibrinogenesis requires the binding of 
pUR4 to the N-terminal type I modules of fibronectin [264], which means that pUR4 
mimics the binding sites on cell surface to the five N-terminal type I modules of 
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fibronectin [151]. On the other hand, pUR4 was compared with STAFF-5 and STATT-
5 peptides. They are crystal structures that depend on fibronectin-binding protein from 
Staphylococcus aureus and they could bind to 2FNI-3FNI and 4FNI-5FNI, respectively, 
with high affinity [244, 265]. The interactions of crystal structures (STAFF-5 and 
STATT-5) which were found with fibronectin modules were used for the pUR4 
sequence [244]. pUR4 was set depending on the EDT sequence at its C terminus for 
2FNI interaction and compared with the STATT-5 sequence. It was shown that 
MVETEDT of pUR4 was more preferable than HTTVEDT sequence of STATT-5 for 
2FNI binding [246]. The same comparison was done for 3FNI interactions and the 
ETGFSG had more favorable energy for this binding depending on the IVTGAV 
sequence of STATT-5. Furthermore, all bacterial fibronectin-binding proteins include 
GEXGE motif that was show by NMR spectroscopy to bind to 8-9FNI modules [213, 
266]. It was also confirmed that collagen type I interacts with 8-9FNI modules by this 
motif and pUR4 contains GESGE sequence which its involvement in collagen binding 
was also confirmed [211, 213]. Therefore, pUR4 was recommended as a strong 
inhibitor of assembly because it has binding sites to 2FNI, 3FNI, 8-9FNI as well as 
collagen type I. The second modified peptide has also functional domains in 
comparison to those of pUR4 and the crystal structures that were mentioned before. It 
includes the SGF fragment which mimics the sequence in pUR4 that interacts with 
3FNI. The sequence DEEDQT in the second modified peptide mimics also EDT which 
was confirmed to interact with 2FNI with high affinity. In the in vitro experiments 
evaluating these modifications, we found an effect on fibronectin accumulation. This 
was also associated with a decrease in cancer growth both in the MDA and in the 
melanoma models. However, the effect in vivo was not improved over the effect of 
pUR4 on growth in the immune competent model using B16 melanoma cells. Even 
though the modified peptide decreased the growth of MDA in vivo possibly more than 
pUR4, this could be due to the low number of replicates we had in this model. The 
modified peptide did not affect the macrophages in the B16 model, which suggests that 
the effect is due to the inhibition of fibronectin. Thus, the change in immune cells in the 
pUR4 treated mice could be irrelevant for the change in growth of cancer.  
The modified sequence was then divided into three individual peptides and 
synthesized to find out which part is responsible for the inhibition of matrix 
accumulation. The fraction of the modified peptides was tested in vitro on MDA cells 
and the fibronectin content was quantified by ELISA. The data showed that the internal 
sequence “peptide B” which contains the 3FNI and 2FNI binding sequence was the best 
one in inhibition of fibronectin accumulation. This part was further divided into three 
parts, but none of these short peptides was better than the pUR4 or the modified 
peptide in decreasing fibronectin accumulation. Thus, while these modifications offer 
promise for the development of a potent matrix inhibitor to take advantage of in the 
therapy of cancer, they fail to offer measurable advantages on matrix accumulation 
over pUR4 or the modified peptide. 
4.3 Changes in the expression of cytokines profile of tumors 
The cytokines produced by immune cells and their involvement in tumor progression 
has been well described [267]. Arginase-1 which is produced by M2 macrophages was 
assessed in the immune cells isolated from MDA-tumors and its expression showed a 
significant decrease in CD11b+ cells isolated from MDA-Kd tumors compared to the 
control tumors MDA-CT. These findings were compatible with the reduced tumor 
growth seen in MDA-Kd tumors because high expression of this molecule is associated 
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with an inhibition of the immune response against cancer and ultimately increased 
cancer growth [268]. These results suggest that the macrophages in the MDA-Kd 
tumors have an immune modulatory phenotype which is associated with the production 
of tumor-growth-inhibiting molecules including iNOS and IFN-γ [260]. I could not 
confirm a change in iNOS mRNA expression of the isolated myeloid cells from tumors 
because of its very low expression and the availability of only a small amount of mRNA.  
Arginase-1 expression was also evaluated in the control tumors treated with the pUR4 
peptide. Its expression in pUR4-treated tumors was significantly reduced compared to 
the control tumors and these findings are consistent with the slow growth of the tumors 
treated with this peptide. This also suggests that the effect of pUR4 on tumor growth 
is similar to that of elimination of endogenous fibronectin produced by tumor cells.  
Based on the change in arginase-1 mRNA expression in Kd and pUR4-treated tumors, 
it seems that macrophages that inhibit tumor growth are dominant in these tumors. 
This also suggests that inhibition of tumor fibronectin production or accumulation could 
increase the immune cell response against cancer. The effect of the modified peptide 
on decreasing cancer growth in the absence of a change in macrophages could be an 
indicator, that only matrix modification is relevant and that the change in the immune 
cells is without major relevance. Alternatively, the change in percentage could be only 
a side effect with the major effect mediated by a change in the behavior of the cells 
present, for example by changing arginase-1 expression. 
 
In summary, these data suggest that decreasing the amount of fibronectin in two 
cancer models diminishes cancer growth. This could be in part due to a change in the 
behavior of the immune cells that infiltrate the tumor. Further studies are needed to 
establish a causal relationship between the inhibition of matrix accumulation and the 
change in macrophage behavior. Even though several modifications failed to result in 
a more pronounced inhibition of cancer growth, this work offers the basis for inhibiting 
matrix accumulation in the development of new therapeutic classes against cancer. 
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5 SUMMARY 
An emerging field in cancer research consists of the study of the role of extracellular 
matrix proteins. The participation of fibronectin in different stages of tumorigenesis by 
different mechanisms has already been confirmed in numerous studies. Therefore, the 
potential of use of fibronectin modulation as a therapeutic approach in cancer might be 
promising. In this work, the effect of peptides that target fibronectin accumulation was 
tested in two different cancer models. 
 
pUR4 is a bacterial peptide which that prevents fibronectin fibril formation. Because 
fibronectin is required for collagen accumulation, this leads to a decrease in collagen. 
The recombinant version of pUR4 was tested in vitro and in vivo in human breast 
cancer cell line MDA and murine B16 melanoma cells. This peptide was then 
synthesized and modified in order to better understand its effect on the immune 
response against tumors and to investigate whether an improvement can be achieved 
by various modifications. 
 
The fibronectin polymerization inhibitor pUR4 diminished fibronectin accumulation by 
MDA cancer cells in vitro and was able to reduce tumor growth in vivo. However, 
growth proceeded nevertheless albeit at a slower rate. This was associated with an 
increase in a subpopulation of immune cells compatible with macrophages (CD11b-
F4/80+) and a decrease in the mRNA expression of arginase in myeloid cells isolated 
from the treated tumors. The suppression of growth was confirmed using a second 
model of melanoma in immune competent mice.  
 
Several modifications were introduced and a new peptide was synthesized, but its 
effect on fibronectin accumulation in vitro was not more pronounced than pUR4. In 
vivo, the modification diminished cancer growth further compared to pUR4 in the 
immune deficient MDA model, but this could not be confirmed in the immune 
competent melanoma B16 model suggesting it is due to the small sample size in the 
MDA model, or that it is not a universal effect. Interestingly, we could not detect a 
change in the macrophages with the modified peptide despite the decrease in cancer 
growth. Attempts at characterizing the best sequence within the modified peptide led 
to short peptides that diminish fibronectin accumulation in vitro, but none was better 
than pUR4.  
 
The data indicate that pUR4 suppresses fibronectin accumulation and leads to a 
decrease in cancer growth. An accompanying change in the mRNA expression in the 
macrophages could contribute to this effect, but causality was not evaluated in this 
work. In summary, matrix manipulation offers new possibilities in suppressing cancer 
growth. 
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